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ABSTRACT 
New technologies allow researchers to produce large amounts of data (e.g. from textual 
and multimedia sources), which represents a challenge for the scientific community. 
Bioinformatics fills the gaps by creating algorithms, tools and methods to process the 
increasing quantity of information. 
The main contribution of this research project was to introduce new and improved 
biomedical informatics methods in the field of primary immunodeficiency diseases 
(PIDs). Patients with these diseases have an increased rate of infections but also 
autoimmune and malignant manifestations. Many of these diseases are very rare with a 
fatal end and often they are misdiagnosed or have a delayed diagnosis. Developing 
software systems within the domain of primary immunodeficiencies is a highly 
challenging task.  
In this study two databases were created and a new classification for PIDs was 
developed. The studies described here use an interdisciplinary approach, based on 
database and data mining technologies, artificial intelligence, machine learning and 
combined data from different disciplines such as molecular biology, genetics, 
immunology, bioinformatics. 
The wide ranging domain of PIDs was investigated at the protein, genetic, and 
clinical level and, based on the analyses of different PIDs. Two databases, 
ImmunoDeficiency Resources (IDR) and IDdiagnostics were developed. IDR is a 
comprehensive knowledge base for PIDs, which includes tools for clinical, biochemical, 
genetic, structural and computational analyses as well as links to related information 
maintained by others. IDdiagnostics is a directory of laboratories performing genetic and 
clinical tests for PIDs. A concept map for the bioinformatics study of PIDs was designed 
for different types of users. The model can be used for different types of hereditary 
diseases. 
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Several computational methods for the classification and clustering of PIDs have 
developed a novel classification of 11 groups, which revealed previously unknown 
features and relationships of PIDs. These methods aim at automating the classification of 
PIDs and therefore would be very useful for the PID research and clinical community. 
Comparison of the classification to independent features such as severity and therapy of 
the diseases, functional classification of proteins, and network vulnerability, indicated a 
strong statistical support. The method can be applied to any group of diseases. 
 
Keywords: primary immunodeficiency, data mining, registries, databases, medical expert 
systems, classification, network analysis, systems biology 
 
 
 8 
ABBREVIATIONS 
AAAAI American Academy of Allergy, Asthma and Immunology 
ACAAI The American College of Allergy, Asthma and Immunology 
AI Artificial intelligence 
AT 
ATM 
Ataxia telangiectasia 
Ataxia telangiectasia mutated gene 
CBR Case-based reasoning 
CVID Common variable immunodeficiency 
CGD Chronic granulomatous disease 
DGS DiGeorge syndrome 
DSS Decision support system 
DT Decision tree 
DTD   Document Type Definition 
EDDNAL European Directory of DNA Diagnostic Laboratories 
EMBL Genetic sequence database by European Molecular Biology 
Laboratory 
GA   Genetic algorithm 
GDB  Genome Database 
GenBank Genetic sequence database by National Center for Biotechnology 
Information 
EPR Electronic patient record 
ES Expert system 
ESID  
HIES 
European Society for Immunodeficiencies 
The hyper-IgE syndromes 
HTML Hypertext Markup Language 
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IDML  Inherited Disease Markup Language 
IDR   ImmunoDeficiency Resource 
IGAD  IgA deficiency 
IE Information extraction 
IFNγ  Interferon γ 
LAD Leukocyte adhesion defect 
MAI Medical artificial intelligence 
MDSS  Medical decision support system 
MES  Medical expert system 
MHCII Major histocompatibility class II 
ML Machine learning    
NLP Natural language processing 
NN Neural network 
OMIM Online Mendelian Inheritance in Man 
PID Primary immunodeficiency 
PIDexpert Primary immunodeficiency expert system 
PDB  Protein DataBank 
ProDom Protein Domain Database 
PROSITE Database of Protein Families and Domains 
SCID  Severe combined immunodeficiency 
SGML  Standard Generalized Markup Language 
SMART Simple Modular Architecture Research Tool 
SNP Single nucleotide polymorphism 
SOAP Simple Object Access Protocol 
Swiss-Prot Protein knowledgebase 
URL Unified Resource Locator 
W3C World Wide Web Consortium 
WAP Wireless Application Protocol 
WAS Wiskott Aldrich Syndrome 
WHIM  Warts-Hypogammaglobulinemia-Infections-Myelokathexis 
WHO World Health Organization 
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XHIM  X-linked hyper IgM 
XLA X-linked agammaglobulinemia 
XLP X-linked lymphoproliferative syndrome 
XML Extensible Markup Language 
XSL Extensible Style Language 
XSLT XSL Transformations 
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1. INTRODUCTION 
Primary immunodeficiencies (PIDs) are a large and heterogenous group of mainly rare 
hereditary disorders of the immune system that often have serious consequences. These 
diseases represent a challenge in their diagnosis and treatment due to overlapping 
symptoms and similarities between diseases. The main manifestations include infections 
but also autoimmune and cancer diseases, granulomatosis, hemophagocytic syndrome, 
angioedema, autoinflammation, thrombotic microangiopathy, or a predisposition to 
allergies. 
Bioinformatics provides a vast amount of different tools that are designed to 
collect the data, analyze it and make predictions when for some reason there is a shortage 
of experimentally defined data or there is a lack of consensus in classification or 
diagnosis. Various databases for collecting information about PIDs exist on the Internet, 
starting from the proteomic, mutational level and ending with the national PID patient 
registry. The results from these databases were evaluated periodically to see whether 
there are differences among different populations and the epidemiological data collected, 
and how the different statistics differ from each other. Classification and network 
analysis methods have been used to characterize, e.g., the spread of epidemics, to 
determine ways to control them, and to identify novel target genes for prostate cancer. 
The aim of this study was to develop new comprehensive knowledge bases for 
PIDs which could integrate all the available PIDs resources on the Internet tailored for 
different types of users. Using the knowledge accumulated in these databases and 
datamining techniques, a mathematical, systematic classification of PIDs was proposed 
which was useful in developing of a decision support system for PIDs. These approaches 
bridge the knowledge bases with diagnostic and therapeutic protocols to be applied 
directly in patient care. These specific applications have been helpful in gene discovery, 
development of other databases, diagnosis protocols and of ICD 11. 
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2. REVIEW OF LITERATURE 
2.1 Primary immunodeficiency diseases  
2.1.1 Background on PIDs 
Integrity of the immune system is essential for defence against infectious organisms and 
their toxic products and for the survival of all individuals. Defects in one or more 
components of the immune system can lead to serious and often fatal disorders, which are 
collectively called immunodeficiency diseases. These diseases have been classified since 
the beginning into two main groups. The congenital or primary immunodeficiencies are 
genetic defects transmitted hereditary that result in an increased susceptibility to 
infectious, autoimmune and cancer manifestations, frequently manifested early in infancy 
and childhood but sometimes clinically detected later in life. Acquired or secondary 
immunodeficiencies develop as a consequence of e.g. malnutrition, disseminated cancer, 
immunosuppressive drugs, infections, especially HIV (Abbas and Lichtman 2005).  
Primary immunodeficiencies (PIDs) are challenging for both scientists and 
clinicians and may manifest with a wide range of clinical symptoms including 
susceptibility to infections, allergy, autoimmune and inflammatory diseases, 
lymphoproliferation and cancer (Marodi and Notarangelo 2007). Currently, more than 
200 PIDs and some 170 PID-related genes are known, many of them reported during the 
last few years. Diagnosis of PIDs may be demanding due to symptoms and signs often 
being discreet, overlapping and variable in many PIDs. Also, the large number of PIDs 
makes the field difficult for non-experts. PIDs (Notarangelo et al. 2004; Stiehm et al. 
2004) are relatively rare, with an incidence varying between 1:500-1:500000 and in some 
cases there are just a few patients globally. Most PIDs present in childhood, but also in 
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the second and third decades of life, for example common variable immunodeficiency 
(CVID). 
The infections in immunodeficiency patients can be mainly categorized in two 
classes. Patients with defects in immunoglobulins, complement proteins or phagocytes 
are very susceptible to recurrent infections with encapsulated bacteria, such as 
Haemophilus influenzae, Steptococcus pneumonia and Staphylococcus aureus. Patients 
with defects in cell-mediated immunity are susceptible to infections with opportunistic 
microorganisms, such as yeast and chickenpox (Roitt et al. 2001). Early detection, before 
serious infections have compromised patient’s general condition, is important for 
prognosis and genetic counseling of the family (Stiehm et al. 2004).  
Primary immunodeficiency disorders were first identified after the introduction of 
antibiotics. Several syndromes of immunodeficiency with characteristic clinical features 
were described before 1940, including mucocutaneous candidiasis by Thorpe and 
Handley in 1929, ataxia-telangiectasia by Syllaba and Henner in 1926, and Wiskott-
Aldrich syndrome (WAS) by Wiskott in 1937 (Stiehm, Ochs et al. 2004). The first patient 
with cellular deficiency was initially described by Glanzmann and Riniker in 1950.  The 
seminal article by Bruton in 1952 reported the first patient with congenital 
agammaglobulinemia who had an excellent response to immunoglobulin replacement 
therapy (Bruton 1952). This discovery, considered to be the birth of the primary 
immunodeficiency field, opened the door to numerous other achievements. Several other 
immune defects were recognized on the basis of their consistent clinical findings or 
inheritance patterns (Buckley 2002). The first case of phagocytic defect was reported in 
1956 (Kostmann 1956). The combination of antibody deficiency with defective cellular 
immunity was first identified in a Swiss infant, Swiss-type agammaglobulinemia (Hitzig 
et al. 1958). The first case of complement deficiency was reported in 1966 (Klemperer et 
al. 1966).  One of the most puzzling conditions was described by Janeway and his 
colleagues in patients with pyogenic infections and enlarged lymph nodes, 
hepatosplenomegaly and hypergammaglobulinemia, which proved to be later X-linked 
chronic granulomatous disease (Buckley 2002).  
From 1961 to 1972 the role of the thymus gland in immune system function began 
to be elucidated with animal models (Miller 1961; Good et al. 1962; Cooper et al. 1965). 
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Different studies in vivo showed cellular immunity to be impaired in patients who had 
congenital hypothyroidism and no thymic tissue at autopsy, pathologic presentation of 
thymic hypoplasia (DiGeorge syndrome) (Miller 1961, Cooper et al. 1967). The first 
insights into the defects of the oxidative metabolism of the phagocytic cells were another 
important discovery during this period (Holmes et al. 1966). A series of technological 
advances in the 1960’s and 1970s helped the investigation of the immune system 
enormously. The 1980s led to the cloning of the genes responsible for many of the known 
primary immunodeficiencies (Kwan et al. 1986; Gatti et al. 1988; Kwan et al. 1988; Puck 
et al. 1989). 
Treatment milestones include the first use of immunoglobulin for immune 
deficiency (Bruton 1952), the first successful hematopoietic cell transplants in humans in 
1968, in three patients with primary immunodeficiencies who received grafts from HLA-
matched siblings (two with SCID and one with Wiskott-Aldrich syndrome) (Gatti et al. 
1968). The first use of a cytokine for the treatment for chronic granulomatous disease 
was reported in 1991 and the first success of gene therapy for X-linked severe combined 
immunodeficiency (Cavazzana-Calvo et al. 2000). 
2.1.2 Genetics of PIDs 
Within the past 20 years major advances in the understanding of the genetic basis and 
molecular mechanism of immunodeficiencies has been made. Increasing understanding 
of these molecular defects has influenced both basic and translational research. More than 
170 distinct genes have been associated with PIDs. Different mechanisms may cause PID 
pathologies, including transcription factors, cytokines and their receptors, cell surface and 
cytoplasmic signaling mediators, cell cycle regulators, DNA modifying enzymes, 
intracellular chaperones and transport proteins. The genetic defects that cause PIDs can 
affect the expression and function of proteins involved in different biological processes, 
such as immune development, effector-cell functions, signaling cascades and 
maintenance of immune homeostasis (Marodi and Notarangelo 2007). In recent years, the 
genetic basis of more than 200 primary immunodeficiencies has been identified and their 
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mode of inheritance as X-linked, autosomal recessive, or autosomal dominant has been 
elucidated (Table 1). 
The first diagnostic measure when considering any heritable disorder is to find out 
the full pedigree and family health history. Families can provide details about potentially 
affected members in past generations. Ethnic and geographical ancestry should be also 
recorded as part of every family history because they may suggest consanguinity or 
increased associated population risks (Ochs et al. 2006). 
The X-linked (XL) immunodeficiency diseases occur in high frequency in males, 
because mutations in genes of the sole copy of chromosome X are uncompensated and a 
single mutation causes overt disease (Table 1). Recessive diseases require defects in both 
alleles of a gene in order for a disease phenotype to manifest. One way is through 
consanguineous marriages such as the interferon γ receptor mutations causing 
susceptibility to mycobacterial infections (Al-Muhsen and Casanova 2008). Another risk 
factor for homozygous recessive diseases is to belong to a genetically isolated population 
in which the same mutation may be transmitted through both maternal and paternal lines 
to the patient because of inbreeding (Table 1). There are few dominant 
immunodeficiency phenotypes. They are characterized by incomplete penetrance, 
skipping generations in family pedigree and/or variable expressivity, and a large 
spectrum of severity among relatives with the same genetic mutation (Table 1). 
 
Table 1. Chromosome locations and inheritance of genes related to PIDs   
Disorder 
 
Gene symbol Gene 
location 
X linked Disorders   
XL chronic granulomatous disease CYBB Xp26 
XL SCID IL2RG Xp13 
XL lymphoproliferative syndrome SH2D1A 
BIRC4 
Xq25 
Wiskott-Aldrich syndrome WASP Xp11.22 
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Disorder 
 
XL agammaglobulinemia 
Gene symbol 
 
BTK 
Gene 
location 
Xq21.3 
XL hyper-IgM syndrome CD40L Xq27 
Glucose 6-phosphate dehydrogenase deficiency G6PD Xq28 
Ectodermal dysplasia with NEMO mutation IKBKG Xq28 
Properdin deficiency PFC Xp11 
Hoyeraal-Hreidarsson syndrome DKC1 Xq28 
Barth syndrome TAZ Xq28 
IPEX syndrome FOXP3 Xp11.23 
AR Disorders   
AR chronic granulomatous disease p22-phox 
p47-phox 
p67-phox 
16q24 
7q11.23 
1q25 
Janus kinase 3 deficiency JAK3 19p13.1 
CD40 deficiency  CD40 20q12-
q13.2 
RAG1 deficiency RAG1 11p13 
RAG2 deficiency RAG2 11p13 
Artemis deficiency DCLRE1C/ 10p 
ZAP70 deficiency ZAP70 8q12 
Adenosine deaminase deficiency ADA 20q13 
Purine nucleoside phosphorylase deficiency PNP 14q13 
MHC class II deficiency CIITA 
RFX-5 
RFXAP 
16p13 
1q21 
13q 
MHC class I deficiency TAP1 
TAP2 
TAPBP 
6p21.3 
6p21.3 
6p21.3 
µ heavy-chain deficiency 
 
IGHM 
 
14q32.3 
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Disorder 
 
λ5 surrogate light-chain deficiency 
BLNK deficiency 
Ig α deficiency 
Ig β deficiency 
Gene symbol 
 
IGLL1 
BLNK 
CD79A 
CD79B 
Gene 
location 
22q11.22 
10q23.2 
19q13.2 
17q23 
ICOS deficiency 
TNFRSF13B deficiency 
CD19 deficiency 
ICOS 
TNFRSF13B 
CD19 
2q33 
17p11.2 
16p11.2 
AID deficiency 
UNG deficiency 
DOCK8 deficiency 
AICDA 
UNG 
DOCK8 
12p13 
17q11.2 
9p24.3 
Leukocyte adhesion deficiency I 
Leukocyte adhesion deficiency II 
Leukocyte adhesion deficiency III 
ITGB2 
SLC35C1 
RASGRP2 
21q22.3 
11p11.2 
11q13 
Griscelli syndrome, type 1 
Griscelli syndrome, type 2 
Griscelli syndrome, type 3 
Myeloperoxidase deficiency 
Glycogen storage disease Ib 
Shwachman syndrome 
MAPBPIPdeficiency 
Hermansky-Pudlak syndrome 2 
MYO5A 
RAB27A 
MLPH 
MPO 
G6PC 
SBDS 
MAPBPIP 
AP3B1 
15q21 
15q21 
2q37 
17q23.1 
11q21 
7q11 
1q22 
Chr.5 
Familial haemophagocytic lymphohistiocytosis 
type 2 
Familial haemophagocytic lymphohistiocytosis 
type 3 
Familial haemophagocytic lymphohistiocytosis 
type 4 
PRF1 
 
UNC13D 
 
STX11 
10q22 
 
17q25.3 
 
6q24 
Interleukin-12 receptor β1 deficiency 
Interleukin-12 (IL-12) p40 deficiency 
IL12RB1 
IL12B 
19p13.1 
5q31.1 
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Disorder 
 
STAT5b deficiency 
IRAK4 deficiency 
UNC93B deficiency 
Gene symbol 
 
STAT5B 
IRAK4 
UNC93B1 
Gene 
location 
17q11.2 
12q12 
11q13 
Autoimmune polyendocrinopathy with 
candidiasis and ectodermal dystrophy 
AIRE 21q22.3 
Cartilage-hair hypoplasia RMRP 9p21-p12 
Epidermodysplasia verruciformis type 1 
Epidermodysplasia verruciformis type 2 
TMC6 
 
TMC8 
17q25 
 
17q25 
Natural killer deficiency FCGR3A 1q23 
Transcobalamin II deficiency TCN2 22q11.2 
Hepatic veno-oclussive disease with 
immunodeficiency syndrome 
SP110 2q37.1 
Ataxia-telengiectasia 
Nijmegen-breakage syndrome 
Ataxia-telangiectasia-like disorder 
DNA ligase I deficiency 
DNA ligase deficiency IV 
Bloom syndrome 
Immunodeficiency, centromere instability and 
facial abnormalities syndrome (ICF) 
ATM 
NBS 
MRE11A 
LIG1 
LIG4 
BLM 
DNMT3B 
 
11q22-q23 
8q21 
11q21 
19q13.2- 
13q22-q34 
15q26.1 
20q11.2 
 
C1q α-polypeptide deficiency 
C1q β-polypeptide deficiency 
C1q γ-polypeptide deficiency 
C1r deficiency 
C1s deficiency 
C2 deficiency 
C3 deficiency 
C4A deficiency 
C1QA 
C1QB 
C1QC 
C1R 
C1S 
C2 
C3 
C4A 
1p36.3- 
1p36.3- 
1p36.3- 
12p13 
12p13 
6p21.3 
19p13.3-
p13.2 
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Disorder 
 
C4B deficiency 
C5 deficiency 
C6 deficiency 
C7 deficiency 
C8 α-polypeptide deficiency 
C8 β-polypeptide deficiency 
C8 γ-polypeptide deficiency 
C9 deficiency 
Factor B deficiency 
Factor D deficiency 
Factor H1 deficiency 
C4 binding protein α deficiency 
C4 binding protein β deficiency 
Decay-accelerating factor (CD55) deficiency 
Factor I deficiency 
MAC inhibitor (CD59) deficiency 
Gene symbol 
 
C4B 
C5 
C6 
C7 
C8A 
C8B 
C8G 
C9 
BF 
CFD 
CFH 
C4BPA 
C4BPB 
CD55 
CFI 
CD59 
Gene 
location 
6p21.3 
6p21.3 
9q32-q34 
5p13 
5p13 
1p32 
1p32 
9q34.3 
5p13 
6p21.3 
19p13.3 
1q32 
1q32 
1q32 
1q32 
4q25 
Familial Mediterranean fever 
Hyperimmunoglobulinemia D with periodic fever 
syndrome 
MEFV 
MVK 
16p13 
12q24 
AD disorders   
WHIM syndrome CXCR4 2q21 
LRRC8 deficiency LRRC8A 9q34.13 
Severe congenital neutropenias, including 
Kostmann syndrome 
Cyclic neutropenia 
CSF3R 
ELA2 
1p35-
p34.3 
19p13.3 
GFI1 deficiency GFI1 1p22 
LAD with RAC2 deficiency RAC2 22q12.3-
q13.2 
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Disorder 
 
Autoimmune lymphoproliferative syndrome type 
II 
Gene symbol 
 
CASP10 
Gene 
location 
2q33-q34 
Autoimmune lymphoproliferative syndrome type 
IIB 
CASP8 2q33-q34 
ALPS type III NRAS 1p13.2 
TLR3 deficiency TLR3 4q35 
Autosomal dominant anhidrotic ectodermal 
dysplasia and T-cell immunodeficiency 
NFKBIA/IKBA 14q13 
DiGeorge-anomaly DGCR 22q11 
Tumor necrosis factor receptor-associated 
periodic syndrome 
TNFRSF1A 12p13.2 
Familial cold urticaria and Muckle-Wells 
syndrome 
Chronic infantile neurological cutaneous and 
articular syndrome 
Granulomatous sinovitis with uveitis and cranial 
neuropathies 
CIAS1 
 
CIAS1 
 
CARD15 
1q44 
 
1q44 
 
16q12 
 
A molecular genetic focus adds precision to the diagnosis and allows genotype 
and phenotype correlations. Genetic studies can confirm a suspected diagnosis of PIDs 
and pinpoint a specific genetic etiology in the absence of other data. They can help in 
genetic counseling.  
Gene testing in PIDs in the past was limited to expert academic laboratories; 
nowadays it is easily available to physicians with a broad range of clinical expertise. 
Such testing can establish or confirm a suspected diagnosis and also may predict future 
disease risk in advance of clinical signs and symptoms, inform reproductive decision 
making, and guide clinicians in selecting the most appropriate therapeutic options (Morra 
et al. 2008).  
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Many PIDs are the result of a single gene mutation, making a molecular diagnosis 
for a patient straightforward. More difficult is to find information on the Internet related 
to a specific lab doing a genetic test for a primary immunodeficiency. Over 170 PID 
genes have been identified and the prevalence of most of the genetic defects is still low. 
Different genetic defects can have a similar clinical presentation, and patients with 
different defects in the same gene can have diverse clinical pictures (Burg et al. 2009). 
For example, Omenn syndrome can result from defects in RAG1, RAG2, DCLERC1 
(Artemis), RMRP, IL/R, IL2RG, or ADA (Villa et al. 2008) (Table 2).  
 
Table 2. Genetic heterogeneity of PIDs (modified with permission from Notarangelo 
and Sorensen 2008) 
PID phenotype Associated gene defects 
T-B+NK-SCID ILDRG, JAK3 
T-B+NK+SCID RAG1, RAG2, DCLERC1 
Omenn syndrome RAG1, RAG2, DCLERC1, RMRP, 
IL7R, IL2RG, ADA 
Agammaglobulinemia BTK, IGHM, IGLL1; CD79A, 
CD79B, BLNK 
CVID TNFRSF13B (TACI), ICOS, 
TNFRSF13C (BAFF-R), CD40L, 
CD19, SH2D1A 
Hyper-IgM syndrome CD40L, CD40, AICDA, UNG 
XL lymphoproliferative syndrome SH2D1A, XIAP 
Familial haemophagocytic 
lymphohistiocytosis 
PRF1, MUNC13B, STX11 
Chronic granulomatous disease CYBB, CYBA, NCF1, NCF2 
Severe congenital neutropenias ELA2, HAX1, GFI1, MAPBP, WASP 
Mendelian susceptibility to mycobacterial 
disease 
IL12B, IL12RB1, IFNGR1, IFNGR2, 
STAT1 
Herpes simplex encephalitis 
The hyper-IgE syndromes (HIES) 
UNC93B1, TLR3 
TYK2, DOCK8, STAT3 
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Certain mutations in PID genes can lead to atypical clinical and immunologic 
presentations. For example, null mutations in RAG1 or RAG2 genes cause T-B-
NK+SCID, hypomorphic mutations in the same gene can associate with Omenn 
syndrome, leaky SCID, or combined immunodeficiency with granulomas (Schuetz et al. 
2008). There is a certain level of phenotypic and genotypic heterogeneity in PIDs (Table 
3), making mutation analysis a useful tool to solve differential diagnosis of complex 
presentations (Notarangelo and Sorensen 2008). 
Table 3. Phenotypic heterogeneity of PIDs (modified with permission from 
Notarangelo and Sorensen 2008) 
Mutated genes Associated phenotypes 
RAG1, RAG2, DCLERC1 SCID, OS, leaky SCID 
LIG4 SCID, LIG4 syndrome 
WASP WAS, XLT, XLN 
SH2D1A XLP, CVID 
RMRP CHH, SCID, OS 
ELA2 SCN, cyclic neutropenia 
 
Molecular diagnostics is important for patients and families and to better understand the 
pathophysiology of the disease. Mutation analysis can provide a definitive and precise 
diagnosis, may help in genetic counseling and treatment compliance, and also help to 
establish a diagnosis in an atypical presentation. Molecular diagnostics enable the 
development of long-term preventive strategies to limit complications and irreversible 
organ damage and permit presymptomatic identification of individuals affected with 
potentially lethal forms of PIDs and prompt timely life-saving interventions, such as 
hematopoietic cell transplantation (HCT). 
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2.1.3 Classes of PIDs  
Originally, PIDs were referred to as rare Mendelian traits associated with multiple, 
recurrent, opportunistic infections in early childhood with fatal course. There are still 
numerous controversies and discussions regarding an accepted definition of PIDs. There 
is no single system of classification for PIDs useful for both educational and clinical 
purposes. Most texts use a functional classification based on the immunological 
mechanism disrupted. These types of descriptive functional categories may overlap to 
varying degrees. 
In 1973, a committee of the World Health Organization (WHO) published the 
first in a series of classifications for PIDs (Cooper et al. 1973) followed by revisions 
(WHO 1983; WHO 1986; WHO 1992; WHO 1995; WHO 1997; WHO 1999). The 
definition and classification of PIDs, based on immunological phenotypes, is now 
reviewed every 2 years by WHO in conjunction with the International Union of 
Immunological Societies (IUIS) Expert Committee (Notarangelo, Casanova et al. 2004; 
Notarangelo et al. 2006; Geha et al. 2007; Notarangelo et al. 2009). Others have used and 
proposed different classification systems (Bonilla et al. 2005; Bonilla and Geha 2005; 
Casanova et al. 2005).  
2.1.4 Decision making in diagnosis of PIDs  
Identification of PIDs is difficult. General practitioners and pediatricians need to consider 
PIDs as a potential diagnosis in any child or adult with repeated infections resistant to 
treatments. Recently, different protocols have been published for the diagnosing of PIDs 
(Folds and JL. 2003; Bonilla, Bernstein et al. 2005; de Vries et al 2006). The 10 warning 
signs of primary immunodeficiency and the 4 stages of testing for PIDs have been 
developed by the Jeffrey Modell Foundation Medical Advisory Board 
(http://info4pi.org). Recently, 12 warning signs for infants were proposed (Carneiro-
Sampaio et al. 2010). 
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All these guidelines and protocols are based on the traditional classification of 
antibody, T lymphocytes, phagocyte and complement deficiencies and require some 
knowledge of the immune system and its defects (Folds and JL. 2003; Bonilla et al. 
2005). These guidelines are aimed at both pediatricians and adult physicians (de Vries et 
al 2006). It is important to take a stepwise approach for the diagnosis of PIDs. First, the 
patient need to be evaluated clinically and immunologically using different diagnostic 
protocols (Conley et al. 1999; Bonilla et al. 2005; de Vries et al 2006) and checked for all 
the warning signs for PIDs (step 1). To define the immunological defects further flow 
cytometric immunophenotyping and functional studies (when applicable) of blood, bone 
marrow, or other specimens are done (step 2). These steps are of great value for guiding 
the selection of candidate genes for molecular diagnostics (step 3). Finally, genetic 
counseling and prenatal diagnostics are facilitated with the identification of a genetic 
defect (step 4). 
Guidelines for the diagnosis of PIDs have been developed jointly by the European 
Society for Immune Deficiencies and the Pan-American Group for Immune Deficiencies 
(Conley et al. 1999). Mutation analysis performed through DNA sequencing is supported 
by analysis of mRNA/cDNA and protein expression and by functional assays to prove the 
disease-causing role of mutations. If these are not available or inconclusive, there are 
bioinformatics tools available that might help estimate the significance of the observed 
DNA changes (Fleisher and Notarangelo 2008). 
2.2 Bioinformatics tools for PIDs 
Bioinformatics tools helpful in PID diagnosis can be divided into several categories 
(Figure 1) (Samarghitean and Vihinen 2009):  
1. General PID resources  
2. Classifications of PIDs helpful for diagnosis  
3. Laboratories for genetic and clinical tests for PIDs  
4. National and international PID patient registries 
5. Mutation databases 
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6. Tools for prediction or prioritization of novel PID candidate genes, and  
7. Decision support systems in PID diagnosis (Table 4). 
 
Figure 1. Categories of bioinformatics tools for PIDs 
 
2.2.1 General PID resources 
Dedicated PID information resources on the web include INFO4PI, RAPID 
(Keerthikumar et al. 2009) and general resources on rare diseases such as ORPHANET.  
INFO4PI is a web service that includes information for over 50 diagnostic and research 
centers worldwide and a registry of experts worldwide. It is the official webpage of the 
Jeffrey Modell Foundation (JMF) and designed for diverse user groups. The medical 
advisory group of the foundation has developed ‘10 warning signs of PIDs’, recently 
updated, and ‘4 stages for immunologic testing’, which have been adopted in many 
countries. Another new development launched by the foundation is the software for 
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primary immunodeficiency recognition, intervention and tracking (SPIRIT) which 
matches patient ICD-9 codes with the 10 warning signs of PIDs. 
Resource of Asian PIDs (RAPID) is a newly developed database which contains 
information about PID genes, protein-protein interactions, mouse knockout studies and 
microarray gene expression profiles in various cells and organs of the immune system 
(Keerthikumar et al. 2009). The website also hosts information on sequence variations 
and expression at the mRNA and protein levels of all genes reported to be involved in 
PID patients.  
ORPHANET provides information on rare diseases for healthcare professionals, patients, 
and their relatives. ORPHANET includes expert-authored and peer-reviewed information 
for rare, mostly genetic, diseases. There is a directory of clinics, clinical laboratories, 
research activities and patient organizations. ORPHANET provides up-to-date 
information about rare diseases in many languages.  
Table 4. Resources on the web for PIDs-related information  
Bioinformatics tools URL 
General PID resources 
INFO4PI 
JMF 
ORPHANET 
PID classifications 
AAAAI 
 
ESID/IUIS 
 
   WHO (ICD10) 
 
http://www.info4pi.org 
http://www.jmfworld.com 
http://www.orpha.net 
 
http://www.aaaai.org/professionals/reso
urces/pdf/immunodeficiency2005.pdf 
http://www.esid.org/downloads/ESID_D
iseases_2009_0.pdf 
http://apps.who.int/classifications/apps/i
cd/icd10online/ 
Registries of diagnostic laboratories 
EDDNAL 
GeneTests 
 
http://www.eddnal.com 
http://www.ncbi.nlm.nih.gov/sites/Gene
Tests 
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Patient registries 
ASCIA 
CEREDIH 
ESID 
IPINET  
USIDnet 
 
http://www.immunodeficiency.org.au 
http://www.ceredih.fr/ 
http://www.esid.org/ 
http://www.aieop.org  
http://www.usidnet.org 
Variation databases 
IDbases 
Other PID mutation databases 
 
RAPID 
 
http://bioinf.uta.fi/IDbases 
http://bioinf.uta.fi/base_root/mutation_d
atabases_list2.php 
http://rapid.rcai.riken.jp/RAPID 
Novel PIDs candidate genes 
PID candidates 
RAPID 
 
(Ortutay and Vihinen 2009) 
http://rapid.rcai.riken.jp/RAPID/SVM 
PID diagnosis tools 
UKPIN 
 
http://www.ukpin.org.uk/ESID/index.ht
m 
 
2.2.2 Classifications of PIDs 
Traditionally, PIDs have been classified into wide categories. The PIDs Classification 
Committee of the International Union of Immunological Societies (IUIS) has provided 
classifications for many years. The essential textbook in the field, Primary 
Immunodeficiency Diseases (Ochs et al. 2006), contains another grouping of PIDs as 
well as the International Classification of Diseases (ICD10). The classification in the 
European Immunodeficiency Society (ESID) online patient database further expands the 
IUIS classification. All these classifications have been developed by experts in the field 
and updated regularly. The methodology used for the classification has not been 
described and many newly discovered PIDs do not fit well within these classifications. 
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Different classification schemes have been developed to discriminate patients with 
common variable immunodeficiency disease, a heterogeneous group of immunological 
disorders characterised by low serum immunoglobulin IgG, IgA and/or IgM, defective 
specific antibody production and an increased susceptibility to bacterial infections. The 
Freiburg classification discriminates patients with a disturbed germinal centre of memory 
B cells and patients with defects of early peripheral B cell differentiation by analysing 
CD21 expression (Warnatz and Schlesier 2008). Another CVID classification 
differentiates patients based on the assessment of class-switched memory B cells and 
total CD27+ B cells including the marginal zone like B cells (Piqueras et al. 2003). The 
EUROClass classification (Wehr et al. 2008) distinguishes patients with less than 1% of 
B cells of lymphocytes (B-) from patients with a higher percentage (B+). A new 
analytical computational approach for phenotype analysis of CVID patients was recently 
described (Kalina et al. 2009). This unsupervised hierarchical clustering analysis enabled 
the definition of clusters of individuals with similar B-cell profiles. 
2.2.3 Registries of diagnostic laboratories 
The diagnosis of immunodeficiencies can be difficult because several disorders may have 
similar symptoms. In some cases early and reliable diagnosis is crucial for efficient 
treatment since delayed diagnosis and management can lead to severe and irreversible 
complications. For many PIDs the definitive diagnosis can be obtained only based on 
both genetic and clinical tests. The physical signs may be non-specific, very discreet, or 
absent. Due to the rareness of PIDs there may not be many laboratories analyzing a 
particular disease.  
Some PIDs laboratory information can be found from general services for 
diagnostic laboratories. The GeneTests service provides an international directory of 
genetic testing laboratories and genetic and prenatal diagnosis clinics. There are also 
expert-authored, peer-reviewed disease descriptions called GeneReviews. The European 
Directory of DNA Diagnostic Laboratories (EDDNAL) has information about DNA- 
based diagnostic services. 
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2.2.4 Databases and patient registries 
A database is a collection of related data with some inherent meaning. A database is 
designed, built, and populated with data from different sources for a specific purpose. In 
medicine databases have been established for some diseases (Cotton et al. 1996). Because 
biological and medical data have many special characteristics, the management of this 
kind of information is a highly challenging problem (Elmasri and Navathe 2004). A 
specific design tailored for these types of data is necessary for the management of 
database systems. 
In the case of primary immunodeficiencies, existing population-based databases are 
limited. Available data are derived from case-based disease registries that collect patient-
specific information from multiple sources.  
Case-based registries usually are designed to improve patient care but can be 
helpful for studying rare diseases. In 1992, the Immune Deficiency Foundation (IDF) 
initiated a registry of U.S. patients with CGD and 5 years later expanded the project to 
include seven other disorders: HIGM, XLA, CVID, WAS, SCID, LAD, and DGS 
(Winkelstein et al. 2000). The registry is also used to collect data related to natural 
history and clinical course, including the response to treatment. IDF assembled a group of 
investigators under the name The United States Immunodeficiency Network (USIDNET) 
to implement an on-line system of the IDF registry.  
Several PID patient registries have been released in different countries during the 
last two decades (Rezaei et al. 2008). The information in them can help in making a 
diagnosis for a patient and provide valuable epidemiological information. For example, 
countries, such as Australia (Baumgart et al. 1997), Spain (Matamoros Flori et al. 1997), 
Switzerland (Ryser et al. 1988), Italy (Luzi et al. 1983), Sweden (Fasth 1982), and 
Norway (Stray-Pedersen et al. 2000) have developed their own registry-based estimates 
of the frequency of PIDs. The ASCIA PID Register of Australia and New Zealand has 
already described the prevalence of PIDs in Australia for 1209 patients in 88 centers 
(Kirkpatrick and Riminton 2007). The Italian Primary Immunodeficiency Network 
(IPINET) collects patient information, including the pedigree, date of diagnosis, 
immunological data and clinical manifestations, laboratory data and information about 
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replacement therapy (Plebani et al. 2004). The Spanish Registry for Primary 
Immunodeficiencies (REDIP) has quite similar contents (Matamoros Flori et al. 1997). In 
2004, the Spanish registry counted 2607 cases from 82 centers. The Iranian PID Registry 
has followed 930 patients over a period of 30 years (Rezaei et al. 2006). 
The ESID patient registry is the largest patient registry (Eades-Perner et al. 2007). 
In December 2011, it contained 15052 patient entries from 89 centers for 142 PIDs. For 
each PID there is an individual database; they all share a common core dataset with 
information about diagnosis, therapy, quality of life and some laboratory data. There are 
also disease-specific data models for some of the most prevalent PIDs. Submission of 
mutation data to the patient registry is combined with IDbases (Piirilä et al. 2006). Access 
to the data is allowed only to the registered users who have obtained permission. 
The same software is used by the United States Immunodeficiency Network 
(USIDnet) for registry of US patients. Currently, the USIDnet data is collected for eight 
PIDs, but soon there will be information for over 30 disorders. Another regional registry 
using the ESID online database system is the Latin American Group for Primary 
Immunodeficiency Diseases (LAGID), which so far includes information for 3321 
patients in 14 countries (Leiva et al. 2007). 
Considering the recent reports from four major registries, antibody deficiencies 
are the most common PID comprising more than half of all patients. Other well-defined 
immunodeficiencies, phagocytes defects, and combined T and B cell immunodeficiencies 
are also relatively common. CVID is the most common PID followed by selective IgA 
and/or IgG subclass deficiency, agammaglobulinemia with absent B cells, ataxia 
telangiectasia (AT), chronic granulomatous disease (CGD), and SCID (Rezaei et al. 
2008). 
Other important PID patient- and treatment-related databases include those by the 
Center for International Blood and Marrow Transplant Research (CIBMTR), a combined 
research program of the National Marrow Donor Program, the Medical College of 
Wisconsin, and the European Blood and Marrow Transplant Group (EBMT). These 
facilitate research into allogeneic hematopoietic stem cell transplantation outcomes 
(Horowitz 2008). SCETIDE is a specific stem cell transplantation database for PIDs, 
which has data going back to 1985. These databases allow addressing questions difficult 
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to answer through clinical trials and may also aid the development of optimal designs for 
prospective clinical trials (Griffith et al. 2008; Gennery et al. 2010). 
 
2.2.5 Variation databases 
Other sources of case-based information are the Internet-based, locus-specific 
immunodeficiency mutation databases established by ESID and expanded by other 
investigators (Smith and Vihinen 1996; Vihinen et al. 1999; Väliaho et al. 2000; Piirilä et 
al. 2006). These databases contain information regarding specific mutations and certain 
clinical features of affected persons. The first Internet-based immunodeficiency mutation 
database, BTKbase, was initiated in 1994 to collect information related to mutations in 
the BTK gene (Bruton tyrosine kinase), which causes XLA. Some 130 similar locus-
specific mutation databases have been developed since then (Piirilä et al. 2006). Mutation 
databases can be used to analyze the types of mutations and their distribution in exons 
and introns, including their location in protein domains. Mutation databases that contain 
clinical information can be helpful in assessing genotype-phenotype relations and 
determining the presence of gene variants in asymptomatic family members (Porter et al. 
2000).  
Data from disease and mutation registries can be used to estimate the minimal 
incidence of a disorder, characterize epidemiologic features, and define a range of clinical 
characteristics in a cohort of patients. Current registries provide incomplete population-
based data regarding the burden of PIDs diseases.  
Although many identified genetic variations in PIDs are novel it is important to 
analyze whether the variation in a patient has been previously described. Information 
about PID-related genetic variations is available from different mutation databases. The 
majority of these registries are in the ImmunoDeficiency mutation databases (IDbases) 
maintained at the IBT Bioinformatics group. Currently, there are 122 freely available 
IDbases, which contain mutation information for 5388 patients from 4513 families 
having altogether 2327 different mutational events. In many IDbases there is plenty of 
information in addition to the description of the actual mutation. The mutation entries are 
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linked to sequence databanks, literature and OMIM (Amberger et al. 2009). The format 
of IDbases is standardized and uniform throughout. Currently, some important changes 
are being made to IDbases. Reference sequences at three levels (DNA, RNA, protein) 
have been developed in collaboration with RefSeqGene 
(http://www.ncbi.nlm.nih.gov/refseq/rsg/ and LRG projects (http://www.lrg-
sequence.org). IDbases will have a stable genomic framework for reporting mutations 
that allows easy integration with other services. The IDbases can provide new insights 
into both genotype-phenotype correlations in patients as well as protein structure-function 
relationships for the encoded proteins. The IDbases are linked to the University of 
California Santa Cruz (UCSC) genome browser (Karolchik et al. 2008) from where the 
mutation data can be easily viewed with PhenCode (Giardine et al. 2007), along with 
other genetic and variation information.  
PID mutation information can be found also in Asian Primary Immunodeficiency 
Diseases. For PID genes and proteins there is information about mRNA and protein 
expression as well as on protein-protein interactions and mouse studies. A tool can 
visualize mutations on protein three dimensional structures (Keerthikumar, Raju et al. 
2009). 
While identification of gene defects and variations has become easy and fast to perform, 
the interpretation of the effects and elucidation of the detailed molecular mechanisms of 
genetic diseases is much more difficult. Disease-related alterations may have diverse 
effects on the structure and function at DNA, RNA and protein levels (Thusberg and 
Vihinen 2009). Numerous methods can be used for predicting the effects of amino acid 
substitutions and are collected in the recently developed Pathogenic-Or-Not pipeline 
(PON-P), which is freely available at http://bioinf.uta.fi/PON-P.  
2.2.6 Prediction of PID candidate genes 
Some bioinformatics approaches have been applied to predict novel PID candidate genes, 
putative novel PID genes were prioritized (Ortutay and Vihinen 2009). The method 
combines information about protein interaction network properties and Gene Ontology 
terms. The analysis was based on a dataset for the immunome, the entirety of genes and 
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proteins essential for mounting immune responses (Ortutay et al. 2007). The approach 
utilizes the protein interaction network information available in the Immunome 
Knowledge Base (IKB) (Ortutay and Vihinen 2009). The identified disease candidate 
genes are mainly involved in cellular signaling including receptors, protein kinases and 
adaptors and binding proteins, as well as enzymes (Ortutay and Vihinen 2009).  
Another PID candidate list of altogether 1442 genes (Keerthikumar et al. 2009) is 
available from RAPID (Keerthikumar et al. 2009). Using a support vector machine 
learning approach the authors used 69 binary features of 148 known PID genes and 3162 
non-PID genes as a training set. Six of the predicted genes have been experimentally 
confirmed to be PIDs genes.  
2.2.7 PID diagnosis tools 
Some services for PIDs diagnosis have been implemented on the web. The multi-stage 
diagnostic protocol designed for non-immunologists (de Vries et al 2006) has been 
converted to linked web pages on the United Kingdom Primary Immunodeficiency 
Network (UKPIN) site. Recommendations for diagnosis and treatment for some PIDs, 
both in English and in Italian, are provided by IPINET. In the CEREDIH, the French 
National Immunodeficiency Centre service, there is information about French PID 
diagnosis centers and laboratories. They also have a decision tree-like schema for 
diagnostic protocol. All the information in this service is written in French. 
More advanced tools for diagnosis are called Medical Expert Systems (MESs). 
These are computer software systems that are based on a set of rules applied to 
knowledge originally extracted from human experts or generated by computational 
analyses. In addition to helping in diagnosis and report generation, MESs can improve 
consistency in decisions, as well as timeliness in decision-making and productivity 
(Samarghitean and Vihinen 2008). MESs can be integrated with other health care 
applications, such as electronic patient records, and systems for prescribing and 
dispensing medicines. 
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2.3 Medical expert systems (MES)  
2.3.1 Definitions and short history of MES 
There are various definitions for electronic decision support systems depending on the 
primary use and on the functions the systems have to perform. Expert Systems (ESs) 
(Gonzalez and Dankel 1993; Nikolopoulos 1997) are computer programs developed to 
contain and use knowledge from human experts. They represent and structure medical 
knowledge, and can supplement or replace man in decision-making. ESs uses a set of 
rules to solve problems that need human expertise and can simulate a dialogue with 
experts. They improve the abilities of experts and increase the consistency and quality of 
problem-solving activities. ESs use techniques from artificial intelligence, machine 
learning, and data mining (Samarghitean and Vihinen 2008). 
Two approaches can be used to define an expert system. The first one is the 
human/artificial intelligence (AI) approach and the second one is the technology–oriented 
approach (Godall 1985; Patel et al. 2009). From the human/AI approach, an expert 
system is a computer system that performs functions similar to those normally performed 
by a human expert (Shortliffe 1993). From the technological approach, an ES is a 
computer system that operates by applying an inference mechanism to a body of 
specialist expertise represented in the form of ‘knowledge’ (Samarghitean and Vihinen 
2008). 
The first computerized decision support system in health care in 1959 was based 
on Bayesian statistics and decision theory. Both logic and probabilistic reasoning were 
shown to be essential components of medical reasoning (Ledley and Lusted 1959). 
During the 1960’s and 1970’s many data driven programs, which used pattern 
recognition techniques, were developed for diagnostic problems.  Since the 1970’s, 
expert systems have mainly utilized artificial intelligence approaches (Blum 1986; 
Shortliffe 1993). For the first generation medical expert systems, such as CASNET 
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(Weiss et al. 1978), INTERNIST-I (Miller et al. 1982) and MYCIN (Buchanan and 
Shortliffe 1984), the ability to reason about the diagnostic process was most important.  
In recent years, artificial intelligence approaches have been integrated with 
multimedia and Internet technologies. Connectionist data-mining approaches (Hripcsak et 
al. 2003) including machine learning (Takeuchi and Collier 2005), artificial neural 
networks (Reategui et al. 1997), and genetic algorithms (Gaal et al. 2005), have been 
applied in health care and medicine for decision support.  
Developed in recent years, Health-e-Child project, produced an integrated healthcare 
platform for European pediatrics (Freund et al. 2006; Branson et al. 2008; Jimeno-Yepes 
et al. 2009). Another goal of the project was to provide uninhibited access to universal 
biomedical knowledge repositories for personalized and preventive healthcare, large-
scale information-based biomedical research and training, and informed policymaking.  
CaseReasoner, a Health-e-Child product tool, helps clinicians to search thousands of 
disease diagnoses, treatments and outcomes to find a child similar to their own patients 
(Freund et al. 2006). Another tool of the project is AITION, which uses semantic tools to 
search medical literature and interviews with clinicians as well as patient data (Freund et 
al. 2006).  
 
2.3.2 Architecture of medical expert systems 
The structure of expert systems can be described and understood in terms of the 
components of the system and in terms of the interchange of the information between the 
components. In the early years, expert systems were written in high-level programming 
languages, usually in LISP and PROLOG. The expert knowledge of the domain and the 
algorithms for applying the knowledge were interwoven and the systems could not be 
easily modified for other applications. From stand-alone consultation systems in 1980s, 
we assist to integration with other healthcare systems such as electronic medical records, 
provider order-entry systems, results reporting systems, e-prescribing systems, or tools 
for genomic/proteomic data management and analysis.  
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Current expert systems have three main components: a knowledge base, an 
inference engine, and a user interface (UI) (Figure 3) (Samarghitean and Vihinen 2008). 
 
 
Figure 2. Structure of an expert system 
 
The knowledge base contains the domain-specific knowledge acquired from experts, 
including object descriptions, problem-solving behaviors, constraints, heuristics and 
uncertainties. The knowledge base is the heart of an expert system and usually is in the 
form of if-then rules. The inference engine finds a sequence in which inferences are 
made. The inference engine is used to reason with the knowledge base. Knowledge 
stored, based on published guidelines, databases, and custom knowledge bases, it is 
translated into active rules. These rules or facts are used for deduction and are part of the 
inference engine capable of fuzzy reasoning. Expert systems also facilitate the users by 
providing an explanation subsystem which explains its reasoning to the users. In some 
systems there is a knowledge base editor for writing and updating the knowledge base. 
Expert systems have the ability to separate problem specific knowledge from general-
purpose reasoning. The user interface applies the knowledge, rules, and local patient and 
clinical data and acts as the front-end of the system for the user.  
Modern expert systems are built in a special software environment, known as, 
expert system shells. These provide more general facilities and an easy way to enter 
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necessary knowledge about the problem domain. Some of the popular software packages 
used include ESTA, EXSYS, XpertRule, ACQUIRE, and FLEX. They produce patient-
specific and situation specific recommendations. Medical expert systems can be 
integrated with other applications, such as electronic patient records, systems for 
prescribing and dispensing medicines, and other information systems used in health 
settings (Figure 3) (Samarghitean and Vihinen 2008). 
 
 
 
Figure 3. A modern architecture of a medical expert system 
2.4 Data mining 
2.4.1 Definitions 
 
Data mining is the process of discovering hidden patterns and trends (information) in data 
(Westphal and Blaxton 1998; Han and Kamber 2000; Soukup and Davidson 2002). Data 
mining is seen as the extraction of implicit, previously unknown, and potentially useful 
information from large data sets or databases. Data mining is an umbrella term and is 
used with varied meaning in a wide range of contexts. Most data mining efforts are 
 39 
focused on developing a finely grained, highly detailed model of some large data set. 
Data mining gives information that wouldn't be available otherwise. When the data 
collected involves individual people, there are many questions concerning privacy, 
legality, and ethics.  
Data mining is at the intersection of machine learning, statistics, visualization and 
databases. Statistics is more theory based and focuses on testing hypotheses, while 
machine learning is more heuristic and focuses on improving the performance of a 
learning agent. Data mining and knowledge discovery integrate theory and heuristics. 
2.4.2 Steps involved in data mining 
Data mining is used to extract valid, novel and potentially useful and understandable 
patterns from data. Preliminary steps include data collection, selection, preprocessing, 
and transformation. Appropriate data is first retrieved from the database, and then 
possibly cleaned and reduced before knowledge discovery. After the discovery step, the 
knowledge will be evaluated manually or on the basis of objective quality criteria. The 
overall flow of the data mining process from data sources to different visualizations and 
data mining tools (Soukup and Davidson 2002) is shown in Figure 4 (Samarghitean and 
Vihinen 2008). Data mining is frequently used for prediction and description. 
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Figure 4. Steps involved in the data mining process 
 
2.4.3 Applications of data mining 
. 
Knowledge acquisition and data mining are important application areas of ML. 
Knowledge acquisition, extracting the knowledge from experts, is the major bottleneck in 
the development of expert systems. Semi-automatic methods can support either the 
experts or knowledge engineers in knowledge acquisition. Data mining, by applying 
different machine learning techniques, allows nearly automatic knowledge acquisition. 
Decision trees (Quinlan 1993), neural networks (Swingler 1996), genetic algorithms 
(Pena-Reyes and Sipper 2000) and nearest neighbor classification are some examples of 
such ML methods. 
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Data mining has been extensively used in industry, banking, government, and 
health care delivery. In medicine it has been used for integrated sources of clinical data, 
inferential probabilistic prediction of risk of ventilator-associated pneumonia (Chapman 
et al. 2001), discrimination between ageing-related and non-ageing-related DNA repair 
genes (Freitas et al. 2011), and between cancerous and non-cancerous cells (Dexter et al. 
2010), population surveillance for signs of bioterrorism, pharmacovigilance (Lindquist et 
al. 2000; Hauben et al. 2005) and predictive data mining (Bellazzi and Zupan 2008). 
In medical data mining applications one of the most important features is a safety 
critical context in which decision making activities should always be supported by 
explanations. The value of each datum may be higher than in other contexts, the data sets 
can be small and report nonreproducible situations and may be further affected by several 
sources of uncertainty. Physicians and researchers deal with such difficulties by 
exploiting their knowledge of the domain. Data mining involves applying variable and 
model selection, evaluating the resulting models and encoding this knowledge and using 
it in data analysis. Data mining problems are often solved by using a mosaic of different 
approaches from computer science, such as multi-dimensional databases, machine 
learning, soft computing and data visualization, and from statistics, such as hypothesis 
testing, clustering, classification and regression techniques. 
Data mining algorithms are developed, tested and/or used by health authorities, 
pharmaceutical companies and academic researchers also in the pharmacovigilance 
domain.  A principle concern of pharmacovigilance is detection of adverse drug reactions 
that are novel by virtue of their clinical nature, severity and/or frequency. There is an 
increased interest in developing database screening tools to assist human reviewers in 
identifying associations worthy of further investigation (Hauben, Madigan et al. 2005). 
Predictive data mining is becoming an essential instrument for researchers and 
clinical practitioners in medicine. Thanks to the integration of molecular and clinical data 
within data warehouses, epidemiological studies and emerging studies in genomics and 
proteomics, the area has gained a fresh impulse. Crucial to such data are those data 
mining approaches which allow the use of the background knowledge, discover 
interesting interpretable and non-trivial relationships, and construct rule-based and other 
symbolic-type models (Bellazzi and Zupan 2008).  
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3. AIMS OF THE STUDY 
The aims of the study were to develop knowledge bases for PIDs which may include 
genetic, proteomic, molecular, epidemiological, clinical information about PIDs and 
could be easily updated and integrated with other knowledge services for PIDs. The 
specific aims were: 
 
1. Build, maintain and update the information in a newly developed genetic and clinical 
test database for PIDs, IDdiagnostics (I). 
2. Refine, maintain and update the information in the ImmunoDeficiency Resource 
(IDR), a knowledge base for PIDs (II). 
3.  Develop a new classification for PIDs based on clinical, pathological and laboratory 
parameters (III). 
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4. MATERIALS AND METHODS 
4.1 Data sources 
 
Different data sources were used to collect and update the information in IDR (II) and 
IDdiagnostics (I). These include: 
1. For clinical data the best evidence on primary immunodeficiency were used: 
online scientific literature (PubMed, immunology journals), immunology books 
(Stiehm et al. 2004; Ochs et al. 2006; Rezaei et al. 2008). 
2. For genetic information electronic databases were used: OMIM (Amberger, 
Bocchini et al. 2009), ORPHANET (Ayme and Schmidtke 2007), GeneTests 
(Pagon 2006), GeneCards (Safran et al. 2002), SOURCE (Diehn et al. 2003), 
PROSITE (Sigrist et al. 2002), Swiss-Prot (Boeckmann et al. 2003), Ensemble 
(Birney et al. 2004), eMedicine (2002; Lundberg 2006). 
3. Direct submissions from clinicians were used for the genetic test and clinical test 
database for IDdiagnostics (I). 
4. Direct communications with clinicians and PID scientists in conferences (ESID 
2002-2010, IUIS 2009), meetings (ESID Prague meeting 2007, 2009, 2010; ESID 
Summer School Bled, Slovenia 2009; ESID Juniors workshop Florence, Italy 
2010; PID Advanced School Sao Paolo, Brazil 2010; ESID Junior Symposium 
Tampere, Finland 2011; ESID Registry Workshop, Freiburg, Germany 2011). 
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4.2 Tools used for developing IDR and IDdiagnostics 
 
For building, maintaining and updating the information in the IDR (II) and IDdiagnostics 
(I) different tools were used. 
Web development tools:  
1. eXtensible Markup Language (XML)  
2. Inherited Disease Markup Language(IDML) 
4.2.1 eXtensible Markup Language 
The Extensible Markup Language (XML) is a standard created by the World Wide Web 
Consortium (W3C) for characterizing the content and structure of documents, designed to 
improve the functionality of the Web by enabling more flexible and adaptable 
information identification and presentation (Väliaho et al. 2005). Information encoded in 
XML is easy to read and understand, and easy to process by computers. In XML files, 
structured data is bounded by tags and attributes. XML tags, attributes and element 
structure provide context information that facilitates the interpretation of the meaning of 
content, thereby making it feasible to develop efficient search engines and agents and 
perform intelligent data mining, etc. The XML allows the separation of content, logic and 
presentation. There are many advantages for XML language (time saving, meta-data 
gives extra meaning to information, useful for indexing, future uses, documents exchange 
etc.). XML is increasingly becoming the preferred method of encoding structured data for 
exchange over the Internet. 
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4.2.2 Inherited Disease Markup Language (IDML) 
 
The Inherited Disease Markup Language (IDML) provides a standard method for 
exchanging genetic and clinical data along with general disease descriptions, diagnostic 
information and links to other related resources (Väliaho et al. 2005). Separation of data 
from the presentation enables the seamless integration of data from diverse sources. The 
IDML format is a published, documented open format, offered especially for the purpose 
of data interchange between platforms and databases in the Internet. The data from the 
IDML format for different systems, e.g. to hypertext markup language (HTML), is 
transformed by using extensible stylesheet language transformations (XSLT) stylesheets. 
The IDML specification and document type definition (DTD) follow the XML standards 
of the World Wide Web Consortium (W3C). 
The fact file data model and the Inherited Disease Markup Language (IDML) 
were developed to facilitate disease information integration, storage and exchange in the 
first place for immunodeficiencies, but in principle for any hereditary disease. The IDML 
is an XML specification and container for bioinformatics data on hereditary diseases. The 
fact file data model schema was defined according to W3C XML specification. The fact 
file data model can be depicted as a tree structure graph where a <FactFile> element is a 
root. Fact files make use of the following specifications, standards and databases: HUGO 
gene nomenclature (Wain et al. 2004), RefSeq (Pruitt and Maglott 2001), Swiss-Prot 
(Boeckmann et al. 2003) and SOURCE (Diehn et al. 2003). 
4.3 Clustering and network analysis methods 
 
In paper (III) we used a systems biological approach to develop a new classification for 
PIDs. Different clustering and network analysis methods were used. 
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Clustering is a process that groups a set of objects into clusters so that the similarity 
among the objects in a cluster is high. There are different types of data clustering 
algorithms: hierarchical and partitional. In hierarchical algorithms, successive clusters are 
found using previously established clusters, while partitioning algorithms determine all 
clusters at once. Hierarchical clusters are either agglomerative (bottom up) or divisive 
(top-down) methods. Agglomerative algorithms begin with each element as a separate 
cluster and merge them in successively larger clusters. The divisive algorithms begin 
with the whole set and divide it into successively smaller clusters (Wang et al. 2005). A 
K-means algorithm assigns each point to the clusters whose centroid is closest. The 
centroids are the points that have the coordinates on a central tendency. The main 
advantage of this algorithm is its simple implementation and computational speed. K-
means maximizes inter-cluster variance and ensures a local-optimal solution on a local 
minimum of variance. 
Network analysis is a methodological tool and a theoretical paradigm to describe, 
explore and understand structural and relational aspects. A network consists of entities 
(nodes) that may represent individuals, organizations, or programs connected by lines or 
arrows, which show some relationship between them. A network can be used for four 
different purposes: as a conceptual model, a description of an existing real-word structure 
or system, a mathematical model, or a simulation (Luke and Harris 2007). The network 
paradigm has four important features:  
1. It is a structural approach focusing partly on patterns of linkages between nodes 
2. It is grounded in empirical data 
3. It makes frequent use of mathematical and computational models and  
4 It is highly graphical.  
Network approaches focus on relationships between subjects rather than relationships 
between subject attributes (i.e. variables). In network analyses, data is typically organized 
in an N-by N square matrix. The data entries represent a relationship between a pair of 
nodes. In many cases, network identification is straightforward, especially when 
boundaries are clear (Salganik and Heckathorn 2004).  
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5. RESULTS 
We developed a procedure for the bioinformatics analysis of PIDs based on the 
experience in our group and previous studies on the development of different knowledge 
bases and systematic classifications for PIDs. The procedure was implemented and 
refined in the studies (I, II, III).  
5.1 ImmunoDeficiency Resource IDR (II)  
The ImmunoDeficiency Resource (IDR) is a knowledge base that integrates a wide 
spectrum of information including clinical, biochemical, genetic, genomic, proteomic, 
structural, and computational data. Over time, IDR has proved to be a valuable resource 
for the community, with an increased numbers of users every year, being integrated with 
other new resources such as RAPID and ORPHANET and cited in prestigious journals 
and books. At the core of the system are Fact files in which are stored in a structured 
form information regarding PIDs: genes, heredity, nosology, taxonomy, mutations, 
protein sequences, online resources, organizations and associations. The fact files are 
XML-based, validated data sources on PID-related information. Each fact file provides 
basic information on diseases and affected genes. The fact files also contain HTML 
hyperlinks to other Internet resources that are accepted to be reliable by the experts and 
are integrated within IDdiagnostics, IDbases and IDR. The fact files act as a quick portal 
to further information on diseases. At present there are 178 factfiles. Stand-alone IDML 
fact files have been generated for each PID (Figure 5) (Väliaho et al. 2005).  
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Figure 5. Factfiles at the core of IDR 
The IDR includes in an organized manner also electronic articles, links to electronic 
journals, e-books, digital atlases, other online health services, instructional resources, 
analyses and visualization tools as well as advanced search routines.  
The IDR contains extensive cross-referencing and links to other services. The IDR 
integrates numerous web-based services e.g. sequence databases (EMBL, GenBank, 
SWISS-PROT), genome information (Ensembl, GDB, UniGene, GeneCard, GenAtlas, 
euGene), protein structural database (PDB), diseases (OMIM), references (PubMed), 
clinical guidelines (ESID/PAGID recommendations), mutation data (IDbases), animal 
models (MGD, FlyBase, SacchDB) and information produced by the IDR team (Väliaho 
et al. 2002). The immunodeficiencies category includes, for example, an Introduction to’, 
and ‘Classification of’, immunodeficiencies web pages. Information about the affected 
genes and loci are linked to corresponding servers. ESID and PAGID recommendations 
for diagnostics criteria for immunodeficiences and other guidelines developed by 
different parties are also distributed. The immunology section includes immunology 
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related data sources such as lectures on immunology and immunodeficiencies. The 
IDbases section contains links to some 122 mutation registries (Piirilä et al. 2006). Most 
of them are maintained by IBT Bioinformatics. The pages for animal models list links to 
knock-outs of immunodeficiency related genes in mice (MGD), Drosophila melanogaster 
(FlyBase) and Saccharomyces cerevisiae (SacchDB). Interest groups for immunologists, 
nurses and patients are listed. There are several societies related to immunodeficiency 
research, care and patients. The immunology laboratories section contains a list of home 
pages of laboratories which are active in the many fields of immunodeficiency research 
including diagnosis, treatment and basic research in such areas as genetic analyses, 
protein structure determination and signal transduction. It is also possible to read about 
immunodeficiency related research programs. Links to immunodeficiency related DNA 
and amino acid sequences are available as well as to three-dimensional structures of 
proteins. Furthermore, a picture gallery and a list of meetings and workshops are 
available.  
IDR has an increasing number of users that demonstrate that the web is an 
effective way to deliver complex and updated information to the medical community. As 
it is shown in the figure below in the IDR there are more than 10000 hits each month 
(Figure 6). 
 
Figure 6. Number of pages requests per month/year in IDR over the time 
 50 
The Internet contains a large amount of pages, but only a few contain information about 
data validation. Many times search engines give thousands of links making it almost 
impossible to trawl through all this information. The most difficult task is usually not to 
find data but to differentiate useful and reliable data from other less important search 
results. In the IDR, the experts check all the data; especially links to external information 
sources, and approve only those sites with solid scientific and medical information.  
The IDR is easy to navigate. The IDR pages are color coded for different interest 
groups: researchers, physicians, nurses, patients and families. By selecting the group of 
interest, the user can get specific pages, such as an introduction written for this particular 
group. This makes it easier for the user to find interesting and useful information for their 
own area. The IDR also provides an advanced text search facility, that can utilize boolean 
logic searches with multiple keywords. IDR is integrated with internal and external 
databases, which makes this site a valuable resource for PIDs and a quick tool to be used. 
The structured data from the IDR facfiles has been integrated as weblinks in 
ORPHANET and in the Asian database for immunodeficiencies (Keerthikumar et al. 
2009). 
5.2 IDdiagnostics (I) 
IDdiagnostics is an online registry that includes worldwide data for genetic and clinical 
tests for PIDs. IDdiagnostics is available online at http://bioinf.uta.fi/IDdiagnostics 
(Figures 7, 8). The service is based on extensible Markup XML and is interlinked with 
internal databases: IDR (II) and IDbases (Piirilä et al. 2006) and with external databases 
OMIM (Amberger et al. 2009), GeneCards (Safran et al. 2002) . 
The submission forms for clinical and genetic tests are available online and also 
in paper format (Figure 7, 8). The genetic test questionnaire includes contact information, 
diseases investigated and details about the test. The clinical test questionnaire contains 
contact information about doctors and laboratories that perform analyses, and details 
about immunological tests. The submission is sent by email to the curators.  
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Figure 7. IDdiagnostics submission form for gene/clinical test information 
After the curation process the data appears online in the Internet database. Searching 
facilities allow users to run text-based search queries. The search engine makes it easy to 
find laboratories for certain diseases, methods, and geographical location. 
 
 
Figure 8. IDdiagnostics and different ways to use it 
 52 
IDdiagnostics increases the availability of genetic and clinical methods for PIDs and 
provides possibilities for accurate diagnosis and fast communication between 
laboratories. Until now, within the genetic tests there are 222 entries for 43 diseases from 
52 centers in 10 countries. In the clinical test database there are 30 entries from 29 
centers in 12 countries. 
Searches from IDdiagnostics are easy by using free text or by limiting the search 
to certain data fields. Gene test laboratories can be searched by disease name (also 
alternative names), gene symbol, OMIM code, laboratory, laboratory location, and free 
text. Similar searches are available for clinical laboratories. The search engine makes it 
easy to find laboratories for certain diseases, methods, and geographical locations. 
5.3 Systematic classification of PIDs (III) 
We developed a method and produced a novel systematic classification of PIDs based on 
clinical signs and features as well as laboratory parameters. Network and clustering 
methods were used to obtain a consensus that was shown to be valid according to a 
number of independent features. 
PIDs related information was collected from several sources (Figure 9). Characteristic 
clinical, pathological and laboratory parameters were identified, combined and optimized 
to 87 informative parameters, which were used with an equal weight in analysis. A 
consensus of at least five independent methods (3 clustering and 3 network community 
methods) yielded a novel classification of 11 groups, which revealed previously unknown 
features and relationships of PIDs.  
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Figure 9. Approach for obtaining novel PID classification 
 
11 well-defined disease clusters (DCs) of at least 4 diseases were identified. There is one 
giant cluster, which contains the majority of the PIDs and some separate clusters and 
singleton PIDs. 1285 pairs of diseases are grouped together by at least five methods out 
of a possible 18721, and out of the 12721 that are grouped by at least one method. The 
results are available in an interactive web page at http://bioinf.uta.fi/PID_classification. 
Most of the clusters are very homogeneous and contain related diseases. These 
groups, which have been exclusively generated based on disease characteristics, indicate 
the power of the method. Other information for the PID genes, proteins and their 
functions further support the classification. In addition, these results are statistically 
significant. 
Clusters III and VII contain (almost) exclusively SCIDs, whereas in cluster IX the 
diseases are related to the complement system and clusters I and XI to phagocyte 
functions; in cluster VIII are fever syndromes, and in cluster X Fanconi anemias. All of 
the known MHC I diseases are in cluster V and all of the MHC II genes are in cluster III. 
The classical complement pathway diseases are in clusters V and IX. In cluster II are 
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diseases related to DNA instability and DNA damage repair, except for G6PC3. Clusters 
IV, V, and VI are the most heterogeneous. Cluster IV contains numerous receptor and 
signaling molecule-related diseases. Some of the proteins behind these disorders form 
transmembrane channels. Cluster V contains mainly antibody and complement 
deficiencies together with some SCIDs. The majority of the cluster VI diseases are 
related to phagocytosis and apoptosis. 
The distribution of characteristics describing independent clinical, functional, 
genetic, and network properties of the diseases and the corresponding genes and proteins 
were investigated in order to test whether the etiologically rather homogeneous DCs 
shared any similarities These features were not used for the original clustering of the 
PIDs.  
The PIDs were divided into four groups according to their severity. Severity was 
not among the symptoms used in our classification because it is not routinely used in the 
clinical description of the diseases. The severity shows a very homogeneous pattern in 
some of the clusters. Diseases in DCs II, VII, and IX belong to two categories, whereas in 
almost all of the remaining clusters there are almost exclusively moderate and severe or 
severe and life-threatening diseases. 
PIDs are treated in a number of ways that can be grouped as: Ig treatment, the use 
of antibiotics, antifungals or antivirals, immunomodulators and hematopoietic stem cell 
transplantation. The data for the treatment of the diseases indicates that the majority of 
the clusters are very homogeneous in regard to treatments and there are clear differences 
between DCs. There are DCs in which all of the diseases are treated with the same 
battery of therapeutic modalities. DCs reliably reflect the properties of diseases, and the 
therapy applied to diseases within DCs is usually similar. 
The distribution of the functional properties in the PID classification shown that 
the majority of the group I proteins are involved in inflammation and cellular immunity. 
Group II and VII proteins have functions as transcription factors involved in humoral and 
cellular immunity. Humoral immunity is most prevalent in DC IV, complement proteins 
in DC IX, and both humoral and complement functions in DC V. Inflammation is the 
function involved in DC VIII.  
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6. DISCUSSION 
Health professionals such as primary immunodeficiency specialists are often forced to 
make decisions about diagnosis and treatment in imperfect conditions, under stressful 
circumstances with incomplete information, in the face of unclear pathology. Because 
new advances are made in the field, clinicians might accommodate new information and 
implement new practices. The diagnosis of PIDs is difficult due to overlapping 
symptoms, which often leads to misdiagnosis and delays in treatment or inappropriate 
treatments. Health professionals and researchers should embrace new technologies, such 
as databases, registries, biobanks and expert systems, in their daily practices as well as 
specific studies, and not be afraid of having their decisions being helped by technologies. 
Available data suggest that these technologies are merely tools that aid our memory 
limitations and facilitate more accurate decisions. 
6.1.1 Databases, biobanks and registries 
 
The IDR fact file is a user interface, which serves as a good starting point to explore 
information on PIDs. For some time now, there have been many advanced search 
facilities in the Internet such as Google, which are able to find very fast web pages that 
contain given keywords. However, the web searches typically turn up innumerable 
completely irrelevant findings, requiring much manual filtering by the user. Database 
searching and accessibility have some difficulties including inaccurate and redundant 
search results, nomenclature issues, lack of internal access, lack of customization and 
differing data formats. New methods are needed for improving search results.  
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Almost all the pages on the Internet have been written in HyperText Markup Language 
(HTML), which it is used for style description. It provides some possibilities for simple 
description about a document. It is able to use special metatags that contain simple 
keywords or more advanced descriptions, but they are very little utilized and only the 
most sophisticated search engines can exploit them. 
There are some efforts to integrate heterogeneous biomedical databases. Some 
level of standardization is required for more automatic integration. In the future, Web 
services will use standard Internet protocols including SOAP, WSDL, and UDDI for 
interoperability with other resources. We developed IDR and IDdiagnostics using XML 
in accordance with the specific types of data. The PID dataset from IDR have been used 
to develop tools for finding new PID candidate genes (Ortutay and Vihinen 2009). IDR 
factfiles were helpful also in developing the PIDs network in paper (III) and RAPID 
(Keerthikumar et al. 2009).  
Developments of intelligent databases (IDSs) and high-performance storage 
systems (HPSS) over the WWW have many advantages. Information sharing, 
collaboration between medical practitioners, on-line discussion, on-line treatment and 
diagnosis are among the features which enable doctors to share their knowledge and 
expertise. Standardized communication protocols facilitate the use of increasing datasets. 
Laboratory techniques, for example genome sequencing, and gene and protein expression 
analysis, will improve the accuracy of diagnoses and help in the discovery of novel 
molecular targets. New machine learning techniques will be developed in the future to 
automate knowledge acquisition and knowledge extraction. Future technological 
evolution may lead to powerful diagnostic tools based on classification algorithms 
developed today as stand-alone systems. They will be integrated into existing devices and 
hospital information systems, which will be part of large national/international databases. 
The current trend in disease diagnosis is to merge efforts towards a complete decision 
support system that also integrates modern tools from gene expression, protein 
expression, analysis of protein interactions, loss of function phenotyping, using RNAi, 
animal models, tissue microarrays, metabolomics, cellomics.  
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In Finland, over several decades large population survey approaches have 
produced datasets on especially non-communicable diseases and their risk factors. In 
these surveys, also biological material, mainly serum samples, have been collected. In 
addition to immediate laboratory analyses, samples have also been stored for future 
purposes. Reliable and comprehensive national administrative registers in Finland 
provide unique possibility for definition of disease endpoints for these cohorts.  
Even though these data sources have been widely utilized and internationally 
recognized in epidemiological research, there are also several challenges in effective 
utilization of data. Instead of utilizing existing data sets, current funding opportunities 
easily drive researchers to new data collection. Resources available at the time of data 
collection restrict the focus of surveys and also sample sizes easily remain too small to 
examine complex associations and rare diseases and disorders. Especially, most of these 
data sets alone are too small to assess genetics of diseases and risk factors. Creation of 
larger, comprehensive datasets is complicated and resource consuming.  
Well-developed epidemiological biobanks could markedly improve the quantity, 
quality and utilization of data and thus increase effectiveness and reduce costs of research 
on the etiology of complex diseases. They could also enlarge the scope and perspectives 
in research and increase national and international collaboration. In this development all 
different stakeholders such as policy makers, researchers, funders and the general public 
would need to have a common understanding of the principles of biobanking and legal 
systems and ethical review mechanisms applied to biobanks should be enabling and fit-
for-purpose. Many practical challenges would need to be solved. On the other hand, lots 
of experience and skills already exist to enhance the development.  
Data on PID patients in epidemiological biobanks in Finland are spread in 
different biobanks for other diseases such as the hematological registry and cancer 
registry. It would be beneficial to merge the data already collected in IDR, IDbases or 
IDdiagnostics with data from biobanks and a national registry specifically targeted at 
PIDs. At the moment there is no national PID registry and the development of such a 
registry would constitute a public health priority for Finland or other countries, such as 
Romania which don’t have these kinds of healthcare systems yet for PIDs. 
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Data from IDR, IDdiagnostics and IDbases have been already integrated into the ESID 
registry, a registry which collects PID information from all over the Europe (Eades-
Perner et al. 2006; Gathmann et al. 2009). Current efforts are under way to standardize 
the information from different national PID registries and centralize at the European level 
in the ESID registry.  
Finland will benefit also by merging the bioinformatics tools developed locally already 
for PIDs with a national registry and a biobank specifically tailored for PIDs and also by 
connecting the data with the ESID registry (Gathmann, Grimbacher et al. 2009), other 
Scandinavian PID registries, the SCETIDE registry and the EBMT registry.  
 
6.1.2 Systematic classification of PIDs 
 
The knowledge accumulated in the IDR factfiles, IDbases and IDdiagnostics was also 
used beside most recent discoveries to develop a systematic classification for PIDs. This 
novel method is based on several clinical, pathological and physiological parameters. The 
new classification shares certain features with previous groupings. For example, the new 
classification indicates that cell type expression cannot be very reliably used for 
classification of PIDs. The obtained 11 disease clusters are very robust due to the 
consensus of at least five methods. The p values show the significance of the 
observations. More detailed subgrouping is available by using the consensus of all the six 
methods. The PID parameters could offer guidelines for medical descriptions of PIDs. 
The classification allows a novel and fresh look at the relationships of PIDs, the genes 
behind them and the encoded proteins. Based on the classification and the parameters it 
might be possible to develop novel diagnostic schemes for PIDs. The correlation with 
other independent information implies that the classification reflects numerous properties 
of the diseases and the genes and proteins mutated in them.  
The previous PID classifications have been based on the cell types in which the 
disease-related genes are normally expressed. Antibody deficiencies, combined PIDs and 
diseases related to phagocytosis are widely scattered in the graph. These heterogenous 
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diseases affect numerous parts of the immune system. The highest concentration of 
SCIDs is in DCs II, IV and VII, whereas antibody deficiencies mainly appear in clusters 
IV and V. Phagocyte diseases are exclusive to DCs I and XI but also appear in DCs IV, V 
and VI. 
Clustering methods are widely used in many fields, such as in microarray data 
analysis. In medicine, cluster analysis has been used in the nosological splitting of 
different phenotypes, to classify patients with chronic pain and to develop a new 
taxonomy for airway diseases. We combined both network and clustering methods and 
used their consensus to obtain a robust grouping for PIDs. Considering the consensus of 
four, five, or six independent methods makes the results robust and independent from the 
individual methods. 
The new PID classification can have several applications. Because it was generated 
independently from the existing classifications using solely mathematical analysis of 
clinical and laboratory parameters, it can be used in evaluation and development of other 
classifications. Disease groups defined by experts and found also by our independent 
approach have a strong indication of their existence. Some other possible applications of 
the new classification are: 
1. Organizing PID and information about them in the IDR 
2. Detailed demographics 
3. Mortality records and  
4. Development of a decision support for PID. 
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7. SUMMARY AND CONCLUSIONS 
In this study we have developed two databases and a procedure for in depth analysis of 
PIDs. The analysis has provided interesting insights into different PIDs relationships at 
clinical and molecular level. 
Online knowledge bases, such as IDR collect and distribute many kinds of 
information, and keep users up-to-date with the deluge of data. Resources for diagnosis 
laboratories, such as IDdiagnostics are frequently used by those wanting to verify a 
suspected PID case. Classification of PIDs and knowledge of candidate genes have many 
applications. New methods, algorithms and ontologies are needed to fully exploit all the 
available data for primary immunodeficiencies.  
IDR, IDdiagnostics and PIDs systematic classification provide a comprehensive 
navigation point for anyone interested in these disorders, whether a physician, a nurse, a 
research scientist, a patient, a parent of a patient or general public. These bioinformatics 
tools contain in a systemized manner, continuously renewed information, which can be 
fast approach and updated. They have proved to be a real help for clinicians, medical 
students and researchers and may help in improving medical care. Newly discovered 
relationships found in biomedical databases like these will potentially lead to better 
understanding between observations and outcomes in PIDs and other fields of medicine. 
The method used for PID classification has built-in statistical output and iterative analysis 
using different inputs leads to alternative classifications useful in gene discovery, 
therapeutic trials, and the development of screening or diagnosis protocols. The 
flexibility and statistical power of these methods make them very suitable for the 
development of evidence-based protocols for diagnosis and therapy, not just of PID, but 
of any other group(s) of diseases. This classification approach bridges the existing 
knowledge bases with diagnostic and therapeutic protocols, which may be applied 
directly in patient care. The new approach proposed (using data warehousing and mining 
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technology in the health care) can influence medical outcomes and merit further studies 
and funding.  
With the rapidly changing landscape of healthcare, these kind of bioinformatics 
tools need to evolve quickly. They should be allowed to choose the functionalities that 
represent the best available ideas in healthcare and should be made compatible and 
interoperable with other IT healthcare systems.  
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Primary immunodeficiencies (IDs) are caused by inherited ge-
netic defects leading to intrinsic defects in cells of the immune
systems. Most IDs are rare diseases and can be difficult to diag-
nose because similar symptoms characterize several disorders.
Mutation detection is the most reliable method in such cases.
These tests are not available at most centers and physicians can
have difficulties in finding laboratories that could analyze the
genetic defects because certain genes are possibly analyzed by
just one laboratory. The IDdiagnostics registry has been estab-
lished to provide information for physicians and other health care
professionals. The database at http://bioinf.uta.fi/IDdiagnostics
contains currently information for the analysis of defects in 30
ID-related genes. Another part of IDdiagnostics is a database
of clinical tests. Laboratories performing these analyses, either
gene or clinical tests, are asked to submit their information to
the database by using a printed form or electronic submission at
http://bioinf.uta.fi/cgi-bin/submit/IDClini.cgi. The clinical test
database contains information about tests for clinical data, im-
mune status, and studies of function, antibody response, cell
function, enzyme assays, clinical function, and apoptosis assays.
Both the services are freely available and regularly updated. The
services aim at increasing the awareness of IDs and helping to
obtain exact and early diagnosis.
KEY WORDS: Immunodeficiency; diagnostics; IDdiagnostics; diag-
nostic laboratories; genetic tests; clinical tests; DNA laboratories.
INTRODUCTION
Primary immunodeficiency disorders (IDs) impair the
function of the immune system. Patients suffering these
intrinsic defects have increased susceptibility to recur-
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rent and persistent infections, but other symptoms are also
common.More than 100 IDs affecting the immune system
are known and several genes have been identified (1, 2).
The immune system consists of a very large number of
molecules and processes, and IDs can therefore be caused
by genetic alterations at many loci (2, 3). A particular ID
can be caused by defects in any one of several molecules
that are required for certain responses, because a defect in
any of the sequential steps may impair the whole system.
Early and exact diagnosis is essential for proper treat-
ment of patients to improve the prognosis in the syndrome
evolution, to minimize the expenses related to the treat-
ment, to optimize health care efforts, and for genetic coun-
seling. There is often also a need for prenatal diagnosis.
In the case of certain IDs early diagnosis is crucial for
lifesaving treatment.
IDs can be difficult to diagnose because similar symp-
toms can be caused by several disorders. A further com-
plication is that many IDs are very rare. The incidences for
IDs vary from 1 in 100 to less than 1 in 2,000,000, and for
many of them the prevalence is below 1 in 100,000. Re-
cently, diagnostic guidelines for some common IDs have
been published (4). In many cases the definitive diagnosis
is based on the analysis of a genetic a defect(s), because
mutation detection is the most reliable method of making
a diagnosis. Due to the rareness of several IDs there are
generally not many centers analyzing a certain disease,
and therefore physicians may have difficulties in finding
laboratories that could analyze the genetic defects. New
genes related to IDs are described frequently. It is diffi-
cult even for researchers within the field to keep track of
all new inventions.
The internet contains plenty of medical information
about IDs.We provide a validated knowledge base of prac-
tically all aspects of IDs in ImmunoDeficiency Resource
(IDR) at http://bioinf.uta.fi/idr/. IDR aims at providing
comprehensive integrated knowledge on ID in an easily
accessible format offering data for clinical, biochemical,
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genetic, structural, and computational analysis (5,6). In
addition, we maintain some 50 ID mutation databases
available on the Internet (3, 5, 7–9).
Here we describe IDdiagnostics, a new Internet-based
service of registries for laboratories performing clinical
and genetic tests for patients with heritable IDs. The
database is designed for physicians, researchers, and other
health care professionals. In addition to providing contact
information, the registry also aims at promoting the ap-
propriate use of genetic services inpatient care as well as
increasing the general awareness of IDs.
IDdiagnostics
The aim of the IDdiagnostics registry (http://bioinf.
uta.fi/IDdiagnostics/) is to collect, identify, describe, and
disseminate information on diagnostic services for IDs.
IDdiagnostics is formed of two independent registries for
laboratories performing genetic and clinical tests, respec-
tively, for IDs. The service is intended for physicians,
researchers, and other medical genetics health profes-
sionals. Laboratories are included in IDdiagnostics on
a voluntary basis. We have contacted numerous persons
from laboratories performing these testsworldwide. There
are in many countries contact persons who are in touch
with local centers. The registry is not complete, which
means that it does not include all possible laboratories
or services. Only those willing to have their informa-
tion posted on the Internet are included. Inclusion is at
no charge. To be included, a completed registration form
available in both electronic and paper form should be
submitted.
According to the guidelines of the services, laborato-
ries are regularly contacted to verify the accuracy of their
information. The curators keep the right to remove infor-
mation for a laboratory if there are problems, e.g., with
time schedule or quality of information.
Submission
Data can be submitted to the registry in differ-
ent ways. The preferred method is Web submission at
http://bioinf.uta.fi/cgi-bin/submit/IDClini.cgi. The forms
are easy to use and usually require just clicking the cor-
rect options from forms. Printable forms are also avail-
able (Figs. 1 and 2), which after completion can be mailed
or faxed to the database curators. The paper and elec-
tronic forms are identical. If the electronic form is used,
submission script formats the information from the filled
form such that it can be added to a database in a simi-
lar fashion as in the MUTbase system for immunodefi-
ciency mutation databases (10). New entries are added to
databases only after curatorial review. The program allows
the user to check the information in the database format
before final submission by pressing the test button. The
submissions are sent by email to the curators. An exam-
ple of an entry in the genetic test database is shown in
Fig. 3.
The submission questionnaires were constructed after
consulting with prominent clinicians in the field. The ge-
netic test form includes contact information, details about
the disease investigated and applied methods, and also in-
formation about the frequency of the analysis and price de-
tails. The clinical test questionnaire contains contact infor-
mation and tests performed for immune status, divided into
complete blood count, quantitative serum immunoglobu-
lins, enumeration of blood cell populations, and evaluation
of functional molecules, and tests performed for studies of
function: antibody response, cell function, enzyme assays,
complement function, apoptosis assays, and others.
Database Management
The IDdiagnostics registry is used and maintained on
the Internet to provide up-to-date information at all times.
Submission forms are programmed using CGI (common
gateway interface) scripts. One of the key features of
the Internet is that it allows different Internet-accessible
databases to be connected to one another through hyper-
text links (11). These hyperlinks allow users to interac-
tively retrieve related information from different Internet
databases. However, there are some problems associated
with hyperlinks (12). A large-scale integrative analysis
needs more powerful tools for database integration and
interoperation (13).
To address these problems, IDdiagnostics is based on
eXtensible Markup Language (XML). Because of its sim-
plicity and self-describingnature,XMLhas beenproposed
as a standard for exchanging data over the Internet. We
created a data model, which follows W3C DOM (The
World Wide Web Consortium Document Object Model,
http://www.w3.org/DOM/) specification.
In addition to the Internet, IDdiagnostics can also
be utilized with WAP (Wireless Application Protocol)-
compliant devices such as mobile phones by using the
BioWAP Service (14, 15). The IDdiagnostics system con-
sists of electronic submission forms, Web-based mainte-
nance routines, automated generation of the distribution
version, a versatile search engine, and updated links to
related services.
Contents of IDdiagnostics
IDdiagnostics is a resource that includes data for ge-
netic and clinical tests on IDs worldwide. Currently in
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Fig. 1. Submission page for IDdiagnostics. Laboratories performing genetic tests are requested to fill out one
form per disease and submit it to the registry.
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Fig. 1. (Continued.)
gene tests there are 79 entries for 30 diseases from 22 cen-
ters in nine countries. In the clinical test database there
are 21 entries from 20 centers in 10 countries (Tables I
and II). Because many of the IDs are so rare it is wise to
perform analyses for certain diseases in only a few labo-
ratories due to, e.g., laboratory and reagent costs. IDdiag-
nostics also provides details related to the analyses. The
number of laboratories analyzing each defect varies from
one to eight. The highest number of centers is available
for the diagnosis of X-linked agammaglobulinemia (8),
Wiskott–Aldrich syndrome (5), RAG1 (6), and RAG2 (6)
deficiencies.
Mutation detection can be done by several methods
(16). Many laboratories use direct sequencing, whereas
others rely on fast screening methods followed by se-
quencing. Only with sequencing is it possible to analyze
all the mutations, however, the majority of the ID-related
genes are so large that primary scanning for the gene
defect within an exon or intron can be more cost- and
time-effective.
Since IDs are rare disorders, only big centers may have
enough samples to run certain analyses on a constant ba-
sis. To get an idea about the time required for diagno-
sis, data are provided for details on the turnaround time,
how often the samples are run, and how many samples
are studied annually. The cost of the analyses varies de-
pending, e.g., on the method used, the type of labora-
tory, and research interest in a particular disease. More
common diseases are analyzed routinely and their diag-
nosis may bear substantial cost. Laboratories can have
special requirements for samples and for their handling.
Also, these data are available in the IDdiagnostics ser-
vice. Physicians ought to consult the gene test labora-
tories before sending any samples to learn about condi-
tions, shipment details, and, e.g., expected time for the
test.
IDdiagnostics databases provide search facilities which
allow users to run text-based search queries. IDdiagnos-
tics searching is easy by using free text search or by limit-
ing the search to certain data fields. Gene test laboratories
can be searched by disease name (also alternative names),
gene symbol (17), OMIM (On-Line Mendelian Inheri-
tance in Man) (18) code, laboratory, laboratory location,
and free text. Similar searches are available for clinical
laboratories. The search engine makes it easy to find lab-
oratories for certain diseases, methods, and geographical
locations.
Thedefinitive diagnostics of IDsdependsongenetic and
laboratory tests since the physical signs may be nonspe-
cific, very discreet, or absent. As a first step in diagnosis,
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Fig. 2. Submission page for IDdiagnostics.
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Fig. 2. (Continued.)
secondary ID and other rare nonimmunological disorders
have to be excluded (2).
The laboratory tests included in IDdiagnostics are listed
in Fig. 2. These tests are used to identify different abnor-
malities within the T and B cell systems, NK cells, phago-
cytes, and components of the complement systems.
When immunodeficiency is suspected the first tests are
for complete blood count (RBC, WBC) with differential
and platelet counts. TheCBCwill establish the presence of
anemia, thrombocytopenia, neutropenia, or lymphopenia.
Significant and persistent lymphopenia is one of the most
relevant signs for primary ID.
The initial screening for B lymphocyte function is the
measurement of immunoglobulins. Ig levels have to be
interpreted with care because of marked alterations with
age. However, concentrations of immunoglobulins cannot
be used as the sole criterion for the diagnosis of primary
ID, because reduced immunoglobulin levelsmay be due to
the loss of Ig when antibody production is normal. Serum
immunoglobulins (IgG, IgA, IgM, and IgE) measured
by different methods including radial immunodiffusion,
radioimmunoassay, and ELISA should be a part of the ini-
tial screening. Limited heterogeneity of immunoglobulins
and abnormal κ/λ light-chain ratios have been observed
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Fig. 3. Example of an entry for the genetic test database.
Table I. Primary Immunodeficiencies in the IDdiagnostics Genetic Test Database
Disease OMIM No. Gene symbol Number of entries
Deficiencies predominantly affecting antibody production
X-linked agammaglobulinemia (XLA) 300300 BTK 8
µ-Heavy-chain gene deletions 147020 IGLL1 2
κ-Light-chain deficiency 147200 IGKC 1
Combined B and T cell immunodeficiencies
X-linked lymphoproliferative syndrome (XLP) 308240 SH2D1A 6
Purine nucleoside phosphorylase deficiency 164050 NP 2
ZAP-70 deficiency 176947 ZAP70 2
CD3γ deficiency 186740 CD3G 1
RAG1 deficiency 179615 RAG1 6
RAG2 deficiency 179616 RAG2 6
Artemis deficiency 605988 DCLRE1C 1
X-linked hyper IgM syndrome (XHIM) 308230 TNFSF5 4
Cytidine deaminase (AID) deficiency 605257 AICDA 1
X-linked severe combined immunodeficiency (XSCID) 300400 IL2RG 6
Jak3 deficiency 600173 JAK3 2
MHCII deficiency (defect in CIITA) 60005 MHC2TA 1
MHCII deficiency (defect in RFX5) 601863 RFX5 1
CD4 deficiency 153390 LCK 1
CVID-ICOS deficiency 240500 ICOS 1
IL7R deficiency 146661 IL7R 1
Familial hemophagocytic lymphohistiocytosis 603552 PRF1 2
Other well-defined immunodeficiency syndromes
Wiskott–Aldrich syndrome (WAS) 300392 WASP 7
Autoimmune lymphoproliferative syndrome (ALPS), defect in TNFRSF6 601859 TNFRSF6 2
Defects of phagocyte function
Autosomal recessive CGD p22phox deficiency 233690 CYBA 2
Autosomal recessive CGD p47phox deficiency 233700 NCF1 2
Autosomal recessive CGD p67phox deficiency 233710 NCF2 2
X-linked chronic granulomatous disease (XCGD) 306400 CYBB 3
Leukocyte adhesion deficiency 1 (LAD1) 600065 ITGB2 3
Chediak–Higashi syndrome 214500 CHS1 1
Griscelli syndrome 214450 MYO5A 1
Interferon γ -associated immunodeficiency
IFN-γ receptor deficiency 107470 IFNGR1 1
Total 79
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Table II. Numbers of Clinical and Genetic Tests and Laboratories, by
Country in IDdiagnostics
Country Clinical tests Genetic tests Number of centers
Australia 1 1
Finland 1 1
France 1 7 3
Germany 10 3
Greece 2 2
Hong Kong 5 2
Italy 3 14 5
Japan 3 2
The Netherlands 19 4
Portugal 1
Spain 1 8 3
Sweden 2 2 4
United Kingdom 8 8
USA 1 11 4
Total 21 79 42
in ID syndromes (2). In addition to the measurement of
serum immunoglobulin concentrations, the assessment of
antibody function is a necessary part of humoral immunity
testing. Titers of natural antibodies (anti-A isohemagglu-
tinin and anti-B isohemagglutinin) and titers of antibod-
ies after immunization with protein antigens (tetanus or
diphtheria toxoids) and polysaccharide (e.g., pneumococ-
cal capsular polysaccharides) are most convenient. Immu-
nizations with live viral vaccines should be avoided when-
ever an ID is suspected. If immunoglobulin levels and/or
antibody titers are decreased, the evaluation should pro-
ceed with more advanced tests of B lymphocyte numbers
and functions. B cell enumeration is performed by assess-
ing the percentage of lymphocytes (e.g., CD19, CD20)
reacting with fluoresceinated antibodies to B cell-specific
antigens as assessed by flow cytometry.
The most valuable tests in cellular ID are T cell, T sub-
set enumeration, and NK cell enumeration (CD3, CD4,
CD8, CD16, CD56) performed by flow cytometry. More
specialized tests of T cell function include the assess-
ment of lymphocyte activation and proliferation in re-
sponse to stimulation with mitogens or antigens (CD69,
CD25, CD71, CD45RO, CD45RA, CD40 ligand). In spe-
cialized laboratories, it is possible to measure the pro-
duction of several cytokines and do other in vitro func-
tional tests such as proliferation and cellular cytotoxicity
assays. Cytotoxic defects are variably present in cellular
ID. In some forms of severe combined ID, enzymes of the
purine nucleotide synthesis pathway (adenosine deami-
nase, nucleoside phosphorylase) are deficient. The evalu-
ation of phagocyte cells imposes the assessment of their
number and function. The number of phagocytic cells can
be detected by using a white blood cell count and dif-
ferential. The assessment of phagocytic cell function re-
quires a number of different assays. In vitro studies of
phagocytic cell metabolism (oxidative burst, phagocyto-
sis, glucose metabolism, oxygen consumption), directed
cell movement (chemotaxis), and bactericidal activity test
are usually available only in specialized laboratories. The
NBT test measures the ability of phagocytic cells to re-
spond with an oxidative burst by measuring the reduction
of nitroblue tetrazolium (NBT). More recently, a method
to measure the metabolic burst of activated neutrophils
by flow cytometry with dihydrorhodamine-123 DHR has
been determined.
The complement system can be evaluated bymeasuring
the rate of hemolysis of sheep red cells (CH50) for the
classical pathway and the rate of hemolysis of either rabbit
or guinea pig cells (AH50) for the alternative pathway. If
defects are seen inCH50 orAH50, individual complement
components have to be analyzed.
DISCUSSION
IDdiagnostics was developed to provide health care
professionals information about ID diagnostic laborato-
ries, to increase the availability of genetic and clinical
methods, and to provide accurate diagnosis for pa-
tients. IDdiagnostics is, to our knowledge, the first
service for the diagnosis of IDs. There are two re-
lated services, EDDNAL (European Directory of DNA
Laboratories; http://www.eddnal.com/) and GeneTests
(http://www.genetests.org/), which provide related infor-
mation about European and respective American genetic
test centers in general. IDdiagnostics differs from these
two by being focused on IDs instead of containing all
diseases. The IDdiagnostics content and resultant entries
were intended to systematically address the need, not met
by the EDDNAL or GeneTests database, for directly ap-
plicable clinical information about genetic and clinical
testing on IDs.
The number of entries in the genetic and clinical test
databases is increasing constantly. The gene test database
currently contains 79 entries, with the most records from
TheNetherlands, Italy, Spain, andGermany (see Table II).
The highest numbers of tests are available forXLA,RAG2
deficiency, and Wiskott–Aldrich syndrome (see Table I).
We plan to improve the registries in the future by adding
information about laboratory accreditation and participa-
tion in quality control schemes. The systems vary widely
between countries. In some European countries, a labora-
tory can be certified by a governmental body to perform
mutation analyses. In the United States laboratory test-
ing is regulated through the Clinical Laboratory Improve-
ments Amendments (CLIA), administrated by the Health
Care Financing Administration (HCFA), the Centers for
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Disease Control and Prevention (CDC), and the Food and
Drug Administration (FDA).
The clinical information in IDdiagnostics is interfaced
with other databases (OMIM, GeneCards, and IDR). The
IDdiagnostics registry provides data that can help to find
centers doing genetic and clinical tests on IDs and form
the basis for future epidemiological and clinical studies
related to the IDs.
The IDdiagnostics registry is also a useful tool for ID
patients and their families,whocanfind themost recent ge-
netic test for a specific disease. IDgene tests offer great op-
portunities for biomedical research and health care. They
play an important role in the understanding of disease
mechanisms. Studies of relationships between gene se-
quence variations and protein structure as well as protein
expression and function are currently major aspects of
biomedical research.
In health care genetic tests are performed for a num-
ber of purposes including prenatal diagnosis, newborn
screening, carrier testing, diagnostic and prognostic test-
ing, presymptomatic testing, predictive testing, and ge-
netic counseling. Genetic screening has also become a
promising tool for early detection of IDs. Once the defec-
tive genes are identified, methods can be devised to tailor
treatment to the specific variation of the individual patient
(pharmacogenomics) or even to attempt to repair or re-
place the affected gene (gene therapy) (19). In all cases
of primary ID, there is a need for selected clinical tests to
confirm or establish the diagnosis. Thus a database which
contains information on clinical tests performed by dif-
ferent laboratories is a real help for clinicians and can
improve medical care.
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Abstract
Background: The ImmunoDeficiency Resource (IDR) is a knowledge base for the integration of
the clinical, biochemical, genetic, genomic, proteomic, structural, and computational data of
primary immunodeficiencies. The need for the IDR arises from the lack of structured and
systematic information about primary immunodeficiencies on the Internet, and from the lack of a
common platform which enables doctors, researchers, students, nurses and patients to find out
validated information about these diseases.
Description: The IDR knowledge base, first released in 1999, has grown substantially. It contains
information for 158 diseases, both from a clinical as well as molecular point of view. The database
and the user interface have been reformatted. This new IDR release has a richer and more
complete breadth, depth and scope. The service provides the most complete and up-to-date
dataset. The IDR has been integrated with several internal and external databases and services. The
contents of the IDR are validated and selected for different types of users (doctors, nurses,
researchers and students, as well as patients and their families). The search engine has been
improved and allows either a detailed or a broad search from a simple user interface.
Conclusion: The IDR is the first knowledge base specifically designed to capture in a systematic
and validated way both clinical and molecular information for primary immunodeficiencies. The
service is freely available at http://bioinf.uta.fi/idr and is regularly updated. The IDR facilitates
primary immunodeficiencies informatics and helps to parameterise in silico modelling of these
diseases. The IDR is useful also as an advanced education tool for medical students, and physicians.
Background
Primary immunodeficiency disorders (PIDs) impair the
function of the immune system. Patients with these intrin-
sic defects have increased susceptibility to recurrent and
persistent infections, and they may also have autoim-
mune and cancer related symptoms. Most PIDs are rare
and the diagnosed patients for a condition are often ran-
domly spread out around the world. More than 150 PIDs
affecting the immune system have been described and
more than 100 genes involved in PIDs have been identi-
fied [1]. The number of mutations, identified in unrelated
families with different PIDs, totals over 4,500 [2].
There is plenty of information related to immunology and
immunodeficiencies on the Internet. General immunome
information can be found e.g. from IMGT [3], AntiJen [4]
and Immunome [5] databases and more specific data e.g.
in ImmTree [6], IDbases [2], SYFPEITHI [7], and Immune
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Epitope Databases and Analyse Resources (IEDB) [8]. The
scattering of the disease-related information in the litera-
ture and the Internet is a big obstacle for those interested
in rare diseases. Users often have problems in finding rel-
evant information and assessing the quality of informa-
tion from the Internet. Biomedical information holds
promises for developing informatics methods for postge-
nomic and personalised medicine. The new knowledge
can be applied in the prevention, diagnosis and treatment
of diseases. Computerised information sources have
many challenges related, for example, to terminology and
ontology building, information extraction from texts,
knowledge discovery from collections of documents,
sharing and integrating knowledge from factual and tex-
tual databases, and semantic annotation. There is a need
for a standardised nomenclature and data form that can
be easily handled by computers and presented on any
platform.
The ImmunoDeficiency Resource (IDR) integrates bio-
medical information related to PIDs into a web accessible
knowledge base. The fact files, which form the core of the
system, integrate biomedical knowledge from several het-
erogeneous and autonomous sources.
This paper illustrates numerous new features and
improvements, which have been implemented since pre-
vious IDR releases [9,10], and details about data collec-
tion and automated database integration. The IDR is
developed to serve anybody interested in PIDs and to pro-
vide relevant, up-to-date and validated information in an
easily understandable and usable format.
Construction and Content
The IDR has been designed and implemented using
eXtensible Markup Language XML [11], a system compris-
ing a native XML database and an XML server. Data within
the IDR is structured into document-centred XML and
SHTML files. The interface to the IDR has been completely
redesigned. It consists of a dynamic layout that can adapt
to different screen sizes, from wide desktop screens to
small mobile devices.
Numerous new features, such as the classification of PIDs,
genes related to immunodeficiency, reference sequences,
protein structures and animal model pages, have been
added. Links are also provided to other IDR-fact file data-
bases [12], IDbases for PID-causing mutations [2], and
IDdiagnostics for PID diagnostic laboratories [13].
The IDR aims to provide comprehensive integrated
knowledge about immunodeficiencies in an easily acces-
sible form, targeting different types of users (doctors, sci-
entists, nurses and patients and their families). The
resource includes clinical, biochemical, genetic, structural
and computational data and analyses. The main headings
of the IDR are General Information, Bioinformatics,
Immunology, and Interest Groups (Fig. 1).
The General Information class
Immunodeficiencies in the IDR are classified according to
the molecular defects criteria [1] with links to the Online
Mendelian Inheritance in Man (OMIM) database [14].
Information about the affected genes and loci are pro-
vided and linked with corresponding services. The ESID
and PAGID recommendations for diagnostic criteria [15],
the American Academy of Allergy, Asthma and Immunol-
ogy (AAAAI) parameters [16], and different diagnostic
guidelines [17] are also included. There is also a list for
PID abbreviations.
At the core of the system are fact files (Fig. 2), which store
information regarding disorders, genes, mutations, pro-
tein sequences, online resources, organisations and asso-
ciations [12]. At present there are fact files for 158
diseases. The user interface allows fast access to the infor-
mation. International Classification of Diseases (ICD)
codes [18] are provided for those diseases where the codes
are available. Each fact file provides basic information
about the disease and the affected gene. The fact files have
hyperlinks to other reliable Internet resources. The fact file
data model and the Inherited Disease Markup Language
(IDML) [12] were developed to facilitate disease informa-
tion integration, storage and exchange. The fact files make
use of the following specifications, standards and data-
bases: HUGO nomenclature [19], Swiss-Prot [20], Gene-
Card [21], and SOURCE [22].
The IDML fact files have been generated for each PID. The
major concepts in the fact files are general information,
clinical information, molecular biology and other
resources – all of which are linked to related information
services (Fig. 1). Each of these elements comprises one or
more additional levels. Table 1 summarised the major
concepts and descriptions of the elements in the IDR-fact
files.
The IDML schema [23], IDML document type definition
file [24], examples of an IDML-document, and documen-
tation on the syntax can be read from [25]. The validation
in IDML fact files is done with the IDML validator pro-
gram, available online at [26].
The Bioinformatics class
The bioinformatics section integrates numerous Web
based services (Ensemble [27], Source [22], EntrezGene
[28], euGenes [29], GeneLynx [30], UniGene [31], Gene-
Card [21], GenAtlas [32]). Reference sequences for PID
genes are available for DNA and RNA from the EMBL
database, and for protein data from SwissProt [20]. When
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available, there are links to the protein structures and vis-
ualisation tools in the PDB [33]. The animal models page
has been updated.
The IDbases [2] section provides, in addition to our own
mutation registries, links to other IDbases. At the moment
we have 115 databases with over 4,500 patient entries.
The Immunology and Interest Group classes
The immunology section lists collections of immunology
related data sources including lectures on immunology
and immunodeficiencies, and links to over 40 online
immunology journals. A new feature is the glossary,
which provides explanations for more than 800 immu-
nology terms. Glossary terms are cross linked by each
other, so by clicking one of these terms, such as 'antigen',
not only is the explanation for the term provided, but also
for a group of terms related to 'antigen'. This gives a broad
overview of immunology terminology, which also makes
it a useful tool for education.
The interest group section contains links to immunology,
immunodeficiency, and nursing and patient organisa-
tions. Several societies are related to immunodeficiency
research, care and patients. The list of meetings and work-
shops is continuously updated.
Utility and Discussion
Accuracy and validation of data
The Internet contains a large number of pages. Search
engines often give thousands of links but usually the most
difficult task is to differentiate the useful and reliable data
from other search results. In the IDR, the experts check all
the data and approve only those sites with solid scientific
and medical information. There will be at least one exter-
nal expert for each immunodeficiency. Nursing and
patient societies are also involved in the data validation
process for their own interest groups.
The IDR is easy to navigate. The pages are colour coded for
different interest groups: researchers, physicians, nurses,
patients and families. By selecting the group of interest,
the user can get specific pages produced and tailored for
the particular group. This makes it easier for the user to
find the most relevant and useful information. The IDR
also provides an advanced text search facility, which can
utilise Boolean logic searches with multiple keywords.
Within a typical search, the user-entered search criteria are
Concept map for the IDR knowledge serviceFigure 1
Concept map for the IDR knowledge service. IDR is composed of web pages grouped in to different class categories and 
a fact file database. The system is integrated with different internal and external databases to serve a wide category of users.
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carried from an SHTML or XML form to a category specific
PERL script, which performs the database queries.
The IDR can be used to discover many kinds of informa-
tion as it is integrated with internal (IDbases and IDdiag-
nostics) and external databases (Fig. 1).
The IDbases have recently been integrated with the ESID
patient registry [34], which collects clinical data for
patients. This collaboration facilitates direct submission
both to the ESID registry and IDbases. A similar arrange-
ment will be made with the US Immunodeficiency Net-
work (USIDNET).
A fact file is a user oriented user interface, which serves as
a good starting point to explore information on hereditary
diseases. The user can find not only information about the
disease nomenclature and classification (OMIM, ICD10),
but also a clinical description of the disease, inheritance
and prevalence. The IDR-fact file facilitates finding infor-
mation about laboratories which perform genetic tests for
PIDs, using direct links to IDdiagnostics [13], GeneTest
IDR user interfaceFigure 2
IDR user interface. Screenshots of the main IDR pages. The new user interface provides faster access to the information and 
different new features, such as classification of diseases (top left), the gene related with the PIDs and their reference sequences 
(top right), glossary terms for immunology (bottom right), and diagnostic tools (bottom left). At the core of the system are fact 
files that provide clinical and molecular information for 158 primary immunodeficiency diseases (centre).
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[35] or ORPHANET [36]. Information for PID related
genes contains the nomenclature, including aliases,
sequences, chromosomal location and maps, variations,
and mutations. The IDR-fact files also contain informa-
tion about protein functions, structure, domains, motifs,
subcellular location and post-translational modifications.
PID researchers will also find in the IDR-fact files lots of
information for each disease to keep up-to-date with the
literature, meetings and different associations in the field.
Future work
In the near future a new tool for faster and more accurate
diagnosis, PIDexpert, will be added. PIDexpert is a medi-
cal expert system, designed to give the diagnostic picture
of PIDs based on symptoms, signs, medical history, phys-
ical findings, and laboratory tests. Future tasks in the
development of the IDR will focus on expanding its
depth, breadth, and scope. The external database updates
will be monitored so that any alterations are mirrored
within the archive. We plan to further develop the IDR
based on user feedback and our interactions with the PID
community.
Conclusion
The IDR contains systematically organised, continuously
updated and validated information that is valuable for cli-
nicians and researchers and can improve the medical care
of PIDs. IDR is the first knowledge service designed to cap-
ture both clinical and molecular information about pri-
mary immunodeficiencies and to address different types
of users. It is validated and will be updated frequently. The
IDR facilitates PID informatics and helps to parameterise
in silico modelling of these diseases. The IDR has many
potential users throughout the PID community, from doc-
tors to patients and from immunoinformaticians to exper-
imental immunologists and structural biologists.
Availability and requirements
The IDR database is freely available for academic use from
the URL: http://bioinf.uta.fi/idr.
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Systematic Classification of Primary Immunodeficiencies Based
on Clinical, Pathological, and Laboratory Parameters1
Crina Samarghitean,*† Csaba Ortutay,* and Mauno Vihinen2*†
The classification of diseases has several important applications ranging from diagnosis and choice of treatment to demographics.
To date, classifications have been successfully created manually, often within international consortia. Some groups of diseases, such
as primary immunodeficiencies (PIDs), are especially hard to nosologically cluster due, on one hand, to the presence of a wide
variety of disorders and, in contrast, because of overlapping characteristics. More than 200 PIDs affecting components of the
innate and adaptive immune systems have been described. Clinical, pathological, and laboratory characteristics were collected and
used to group PIDs. A consensus of at least five independent methods provided a novel classification of 11 groups, which revealed
previously unknown features and relationships of PIDs. Comparison of the classification to independent features, including the
severity and therapy of the diseases, functional classification of proteins, and network vulnerability, indicated a strong statistical
support. The method can be applied to any group of diseases. The Journal of Immunology, 2009, 183: 7569–7575.
P rimary immunodeficiencies (PIDs)3 are a large and heter-ogenous group of disorders that have been organized man-ually into different categories (1–8) sometimes without a
consensus. PIDs are mainly rare hereditary disorders of the im-
mune system that often have serious consequences (1, 2). These
diseases represent a challenge in their diagnosis and treatment due
to overlapping symptoms and similarities between diseases. Infec-
tions are the hallmarks of PIDs (1, 9–11). A diagnosis will often
be considered when infections are frequent or severe, resistant to
standard therapies, or caused by unusual (opportunistic) organ-
isms. Other manifestations include autoimmune (12, 13) and can-
cer diseases (14), granulomatosis (15), hemophagocytic syndrome
(16, 17), angioedema (18), autoinflammation (19–21), thrombotic
microangiopathy, or predisposition to allergy.
Clinical descriptions have already been made for more than 200
PIDs (4, 7, 22), for which 167 genetic etiologies have been de-
scribed. PIDs have historically been defined and classified accord-
ing to immunological phenotypes (3). Before molecular analyses
were widely available, PIDs were classified according to the af-
fected immune function, as follows: Ab production (B cells), cel-
lular immunity (T cells) or both (combined immunodeficiencies),
phagocyte function (neutrophils, monocytes), and complement ac-
tivation, etc. This classification has been useful for certain practi-
cal purposes, but not from the mechanistic point of view, because
many PIDs do not easily fit into the scheme. On clinical grounds,
immunodeficiencies can be classified into two broad groups ac-
cording to whether all features are the result of the immune defect
(immunodeficiency syndromes) or whether many, even prominent
ones, cannot be explained by the immune defect (syndromes with
immunodeficiency).
The behavior of even the most complex of systems is based on
the interaction of their components. These components can be re-
duced to a series of nodes that are connected to each other by links,
which together form a network (23). Most real networks in tech-
nological, social, and biological systems share common designs
that are simple and quantifiable. In medicine, network analysis has
been used to characterize, e.g., the spread of epidemics (24), to
determine ways to control them (25), and to identify novel target
genes for prostate cancer (26).
When networks formed from diseases, the involved genes, and
their phenotypes have been investigated (27–29), only a few PIDs
have been included. Information about a protein interaction net-
work for the immunome (30) has been used together with gene
ontology terms (31) to predict novel PID candidate genes (32).
In this study, our goal was to develop a systematic, mathemat-
ical classification of PIDs. Previous PID classifications have been
derived from observational correlations between pathological and
clinical features. The foundation of the method is the description of
the diseases based on 87 clinical and laboratory parameters.
Altogether, six methods belonging to two categories were used to
organize the diseases based on the characteristics. Three clustering
methods were applied to the multivariate problem to form disease
groups in which members are most similar to each other (33).
The other three methods are from the emerging field of community
analysis of networks. A community is a set of nodes with many edges
(connections) inside the community and few edges outside it. Com-
munity analysis is a powerful tool for finding groups in interconnected
entities (34–36); therefore, PIDs interpreted as a network can be an-
alyzed this way, and diseases strongly associated with each other can
be identified. Our systematic approach can be applied for classifying
any other disease group.
Materials and Methods
To obtain a systematic classification for PIDs, a novel approach was de-
veloped. The method applies advanced computational tools for clustering
and network analysis. We used altogether six methods to group PIDs based
on characteristics that they share. Three of the methods were for clustering,
and three for network community analysis.
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Immunodeficiencies and selection of the parameters
Data for PIDs were collected from the ImmunoDeficiency Resource (IDR)
(4), IDdiagnostics (37), IDbases (38), and literature (1, 2, 5–7, 39–43).
Only detailed reports with statistical information including clinical symp-
toms and measured laboratory values characterizing PIDs were included.
When diseases without specific symptoms were excluded, there were al-
together 194 PIDs left.
For each disease, all signs, symptoms, and laboratory values men-
tioned in the literature were collected. The initial list contained 420
parameters. Parameters characterizing only one to four diseases were
omitted or merged to others.
For example, IgM lymphoma, which is according to the literature as-
sociated only with hyper-IgM syndrome type 2, was merged to the more
general term of other malignancies. Similarly, encephalitis, meningoen-
cephalitis, meningitis, conjunctivitis, iritis, episcleritis, and brain abcess
were grouped to a more general term of CNS infections. Cerebellar ataxia,
pathognomonic for ataxia-telangieactasia, and ataxia-telangieactasia-like
disease were merged to neurological or CNS abnormalities together with
other signs, such as peripheral neuropathy, speech delay, and convulsions.
Finally, after iterative process, we had 87 informative parameters (supple-
mental Table S1).4 All of the parameters had an equal weight in the
analysis.
Cluster and network community analysis
Cluster and network analyses were performed in the R statistical environ-
ment (44) using the igraph (45) and cluster program libraries. Three dif-
ferent variations of K-means clustering were used to analyze the dataset.
The Clustering Large Applications (clara) method computes a list repre-
senting the clustering of the data into k clusters. Partitioning Around Me-
doids (pam) partitions (clusters) the data into k clusters around medoids,
which are representative objects of a dataset from which the distances to
the other points in the cluster are computed. The Fuzzy Analysis Clustering
(fanny) method computes a partition grouping of the data into k clusters.
The number of clusters was chosen by maximizing the average width of the
clusters. In fuzzy clustering, data elements can belong to more than one
cluster, and thus, each disease has a set of membership levels, which in-
dicate the strength of association to each cluster.
Three methods were applied to find highly interconnected parts of the
network. Community structure via short random walks is a walktrap com-
munity analysis, which searches for densely connected subgraphs, i.e.,
communities (34). When moving from one node to a connected one, short
random walks tend to stay in the same community. The second method
uses community structure detection based on the leading eigenvector of the
community matrix (35). The method looks for densely connected sub-
graphs by calculating the leading nonnegative eigenvector of the modular-
ity matrix of the graph. The third method tries to find communities in
graphs via a spin-glass model and simulated annealing (36).
Combination of clustering and network results
The data for PIDs are incomplete because in many diseases just a few, even
a single, patient was known, and therefore, the most prominent signs were
difficult to define. In rare diseases, some symptoms may occur frequently
just by chance. Therefore, to obtain the most reliable and robust grouping
and a consistent and robust view of the disease grouping patterns, a con-
sensus classification based on the co-occurrence of the diseases in four,
five, or six methods was generated. Using this approach, the results are
expected to be independent from the biases of the individual methods.
Statistics
To evaluate which of the binary parameters significantly supported the
identified disease clusters, we tested whether a parameter had significantly
different distribution in the individual clusters compared with the entire
dataset by calculating p values using the hypergeometric distribution. The
threshold for significance used was a p value 0.05. A similar evaluation
was performed for the binary clinical and functional properties of the dis-
eases and respective proteins.
Correlation of disease clusters to clinical, genetic, functional,
and network properties
The consensus network graph was used to visualize a number of properties
for the diseases, and involved genes and proteins. Information about the
prevalence of the PIDs was obtained from the IDR (4) and other sources (1,
2, 40, 46). When the prevalence was not known and only a few cases were
reported in literature, it was assumed to be !1/107. Data on inheritance
were retrieved from the IDR and literature (1, 2, 6, 40). For treatment
modalities, the most common treatments were listed for each disease (1, 2,
39). Functional classifications of the proteins in the immunome (47) were
obtained from the Immunome Knowledge Base (48).
Results
PID network
Novel PID grouping was obtained by applying altogether six meth-
ods for clustering and network analysis. Our approach revealed
associations that were not previously obvious and led to the iden-
tification of distinct novel groups. Fig. 1A shows the results when
at least five methods agreed on the clustering. The diseases are
indicated by the affected genes, when known. If all six methods are
required to agree, the only difference is that the 11 major groups
are divided further to smaller subgroups. There is one giant cluster
that contains the majority of the PIDs and some separate clusters
and singleton PIDs. Some details of the classification may change
in the future when more information becomes available, yet still
the major features will remain. In the consensus graph for the PIDs
(Fig. 1A), 1,285 pairs of diseases are grouped together by at least
five methods of a possible 18,721, and of the 12,721 that are
grouped by at least one method. The results are also available in an
interactive web page at http://bioinf.uta.fi/PID_classification.
Disease clusters
The analytical approach combining six different and independent
methods provides a highly robust classification when at least five
of the methods were required to agree on the grouping details. The
dendogram reveals 11 well-defined disease clusters (DCs) of at
least 4 diseases (Fig. 1A). First, we analyzed the nature of the PIDs
in the clusters and then investigated the properties of the diseases
and the corresponding genes and proteins in the clusters.
Most of the clusters are very homogeneous and contain related
diseases. An overall view of the DCs shows that clusters III and
VII contain (almost) exclusively SCIDs, whereas in group IX the
diseases are related to the complement system and in DCs I and XI
to phagocyte functions; in DC VIII are fever syndromes, and in DC
X Fanconi anemias. All of the MHC II genes are in cluster III, and
all of the known MHC I diseases are in cluster V. The classical
complement pathway diseases are in clusters V and IX. Diseases in
cluster II are related to DNA instability and DNA damage repair,
except for G6PC3. DCs IV, V, and VI are the most heterogenous.
Cluster IV contains numerous receptor and signaling molecule-
related diseases. Some of the proteins behind these disorders form
transmembrane channels. DC V contains mainly Ab and comple-
ment deficiencies together with some SCIDs. The majority of the
group VI diseases are related to phagocytosis and apoptosis. All of
the groups have strong statistical support (supplemental Table S2).
These groups, which have been exclusively generated based on
disease characteristics, indicate the power of the method. Other
information for the PID genes, proteins, and their functions further
support the classification (Fig. 1, B–E). Also, these results are sta-
tistically significant (supplemental Table S2).
The previous PID classifications have relied heavily on the cell
types in which the disease-related genes are normally expressed.
Thus, one of the major differences to these is that Ab deficiencies,
combined PIDs, and diseases related to phagocytosis are widely
scattered in our graph (Fig. 1). These diseases are very heteroge-
nous in their symptoms and signs, and affect numerous parts of the
immune system. The highest concentration of SCIDs is in DCs II,
IV, and VII, whereas Ab deficiencies mainly appear in clusters IV
and V. Phagocyte diseases are exclusive to DCs I and XI, but also
appear in DCs IV, V, and VI.4 The online version of this article contains supplemental material.
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To test whether the etiologically rather homogeneous DCs
shared any similarities, the distribution of characteristics describ-
ing independent clinical, functional, genetic, and network proper-
ties of the diseases and the corresponding genes and proteins were
investigated. These features were not used for the original cluster-
ing of the PIDs.
The PIDs were divided into four groups according to their se-
verity. Severity was not among the symptoms used in our classi-
fication because it is not routinely used in the clinical description
of the diseases. SCID is a pediatric emergency situation because
the condition is life threatening, whereas some of the other PIDs
are just mild. In fact, the vast majority of PID cases have been
thought to remain undiagnosed due to mild symptoms. The sever-
ity shows a very homogeneous pattern in some of the clusters (Fig.
1B). Diseases in DCs II, VII, and IX belong to two categories,
whereas in almost all of the remaining clusters there are almost
exclusively moderate and severe or severe and life-threatening
diseases.
PIDs are treated in a number of ways that can be grouped to a
small number of categories, including Ig treatment, the use of an-
tibiotics, antifungals or antivirals, immunomodulators, and the re-
constitution of the immune system by (haploidentical) bone mar-
row transplantation or hematopoietic stem cell transplantation. The
data for the treatment of the diseases in Fig. 1C indicate that the
majority of the clusters are very homogeneous in regard to treat-
ments and there are clear differences between DCs. There are DCs
in which all of the diseases are treated with the same battery of
therapeutic modalities, and in almost all the clusters some of the
therapeutic options can be used for all of the coclustered PIDs.
Also, based on these results, the DCs reliably reflect the properties
of diseases, and the therapy applied to diseases within DCs is
usually similar.
The cellular functions have been determined for all the genes
and proteins required in the immunome (entirety of immune sys-
tem) (49). There are functional groups for, e.g., the surface recep-
tors in clusters of differentiation classification, chemokines, and
their receptors, humoral immunity proteins, and those involved in
cellular immunity, Ag processing, and transcription factors. The
distribution of the functional properties in the PID classification is
shown in Fig. 1D.
The majority of the group I proteins are involved in inflammation
and cellular immunity. Group II and VII proteins have functions as
transcription factors involved in humoral and cellular immunity. Hu-
moral immunity is most prevalent in DC IV, complement proteins in
DC IX, and both humoral and complement functions in DC V. In-
flammation is the function involved in DC VIII. Many of the proteins
have several classifications because they are typically overlapping.
Also, at this level, the grouped proteins and diseases share many com-
mon properties because the functions are very homogeneous within
DCs and differ between them.
Vulnerability is a systems biology measure that indicates how
crucial a certain node is for the network (30). Vulnerabilities of
proteins in the immunome protein interaction network were
color coded compared with the average vulnerability in the en-
tire network (Fig. 1E). There are some clusters in which the
vulnerabilities are related, especially those in DCs III, VI, and
VII. The most vulnerable diseases are widely scattered through-
out the network. Only some of the SCID proteins that are re-
lated with the most severe PIDs are highly vulnerable. Also,
previously, the vast majority of disease genes were shown to be
peripheral in the network (27).
Inheritance pattern (supplemental Fig. S1) and prevalence (sup-
plemental Fig. S2) did not show any correlation within DCs at all.
This was expected because these characteristics are not likely to
affect the etiology of diseases.
Discussion
We developed a novel approach for nosology and produced a sys-
tematic classification of PIDs based on parameters across several
clinical, pathological, and physiological dimensions. Our approach
combines existing clustering and network partition methods to
classify these diseases. The new classification shares certain fea-
tures with previous groupings, yet is different in a number of de-
tails. For example, the new classification indicates that cell-type
expression, which has previously been one of the major classifi-
cation criteria, cannot be very reliably used for classification
of PIDs.
Clustering methods are widely used in many fields, such as in
microarray data analysis. In medicine, cluster analysis has been
used in the nosological splitting of different phenotypes, for ex-
ample in Marshall and Stickler syndromes (50, 51), and more re-
cently to classify patients with chronic pain (52) and to develop a
new taxonomy for airway diseases (53, 54). Because the disease
data were not complete due to many of the PIDs being extremely
rare, we combined both network and clustering methods and used
their consensus to obtain a robust grouping for PIDs. Considering
the consensus of four, five, or six independent methods makes the
results robust and independent from the individual methods.
Comparison with previous classifications
Previous in silico disease classification methods have been based
on shared genes in disorders (27), protein interactions (55), protein
complexes (28), or tissue-specific gene expression (29). For ex-
ample, Human Phenotype Ontology terms describe clinical fea-
tures and can be used for disease grouping (56). However, because
only a few PIDs were included in these classification studies, we
unfortunately cannot compare our results with them.
The new PID classification differs in details from those pub-
lished earlier. The most comprehensive classification with the larg-
est number of PIDs is from the European Society for Immunode-
ficiencies (ESID) registry (7) based on the International Union of
Immunological Societies classification of 150 diseases (6). This
scheme contains seven defined disease groups. The IDR uses and
expands the classification (from Ref. 2) in 11 classes. The Amer-
ican Academy of Allergy, Asthma, and Immunology, the Ameri-
can College of Allergy, Asthma, and Immunology, and the Joint
Council of Allergy, Asthma, and Immunology have classified 97
PIDs in 5 groups (39). The International Classification of Diseases
(ICD10) contains 100 PIDs in 10 categories (8). These classifica-
tions have been useful, although they have disagreed on a number
of disorders. The task of classifying the widely variable PIDs is
hardly any more possible to do manually due to the very high
dimensionality of the data. A systematic, mathematical classifica-
tion can be used as an alternative or complement approach to the
existing methods.
The earlier classifications were color coded and visualized in
supplemental Fig. 3. The previous studies contained only subsec-
tions of the PIDs. The color codes were also chosen so that inter-
classification comparisons are possible because related diseases in
the different groupings have the same colors. The more homoge-
neous the color is within a cluster, the more similar the classifi-
cations are. The IDR and ESID classifications agree very well in
DCs I, II, IV, V, VII, VIII, IX, X, and XI. ICD10 agrees well in
DCs III, V, VII, IX, X, and XI. There are, however, only 100 PIDs
in the ICD system. The American Academy of Allergy, Asthma,
and Immunology grouping behaves similarly to ICD, except for
DC X, diseases that are not included at all. In conclusion, the novel
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FIGURE 1. Consensus for the six methods used to group the PIDs. A, Relationship of the diseases. The white rectangles indicate the grouping of diseases
by five (those attached to the first black bullet from the PIDs root) and six (the second bullet) methods. Diseases are indicated by the systematic names
of affected genes, when known. Otherwise, the following names were used when no genes are identified in relation to the disease: AR-HIES, autosomal
recessive hyperimmunoglobulin E recurrent infection syndrome; CMC, chronic mucocutaneous candidiasis; CVID, common variable immunodeficiency;
FHL1, familial hemophagocytic lymphohistiocytosis type 1; HIGM4, hyper-IgM syndrome type 4; SADNI, specific Ab deficiency with normal Ig con-
centrations; THI, transient hypogammaglobulinemia of infancy; thymoma, thymoma with immunodeficiency (Good’s syndrome); and XLA/GHD, X-linked
hypogammaglobulinemia with growth hormone deficiency. When one gene is involved in more than one disease, the following abbreviations were used:
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classification agrees with numerous features in the earlier group-
ings. All of the previous classifications have a smaller number of
groups, which are typically divided in the new nosology. There are
also a number of diseases that are not consistent with the novel
classification, or with the other previous groupings. The systematic
mathematical approach is capable of solving these cases and places
the diseases in groups using solely the given parameters.
Parameters characterizing primary immunodeficiencies
In PIDs, the signs and symptoms of infections may be repetitive,
severe, or refractory to therapy and caused by organisms with low
virulence (39). We grouped the parameters for infections accord-
ing to microbial taxonomy and site of infection.
Autoimmune diseases and malignancies are complications of
many immunodeficiencies. Based on the frequency of associations
with autoimmune diseases, PIDs can be grouped in three groups,
as follows: systematic ("80% of the patients with the disorder
have autoimmune disease symptoms), strong (20–80%), and mild
(!20% of the patients) and absent (12, 57). Some PID patients
appear susceptible also to atopy and lupus-like syndromes (58).
Malignancies occur with great frequency in certain immunode-
ficiencies. The types of malignancies depend on the PID, the age
of the patient, and any possible viral infection(s). B cell malignan-
cies, especially non-Hodgkin’s lymphomas, are predominant.
Other types of malignancies encountered in PIDs are T cell ma-
lignancies and leukemia (14).
Problems in lymphoproliferation (hepatomegaly, splenomeg-
aly, lymphadenopathy) are typical for some PIDs. EBV infec-
tion is associated with many lymphoproliferation-linked immu-
nodeficiencies (59 – 61).
Some PID patients have chronic respiratory problems, such as
asthma, chronic obstructive disease, chronic inflammatory lung
disease, emphysema/lung cysts, or interstitial pneumonia (62–65).
Cardiovascular diseases such as congenital cardiac anomalies, car-
diomyopathy, and hematologic abnormalities are found in certain
PIDs (66, 67).
Some of the gastrointestinal diseases are associated with PIDs,
including esophageal atresia, Crohn’s disease, chronic inflamma-
tory bowel disease, ulcerative colitis, granulomatous colitis, celiac
disease, malabsorption, Hirschprung disease, and anal stenosis (15,
68–70). Hepatobiliary tract diseases in PID patients include stor-
age liver disease, hepatic vascular occlusion disease, and scleros-
ing cholangitis (71, 72). Kidney diseases associated with PIDs in-
clude renal anomalies, renal dysfunction, amyloidosis, renal
failure, IgA nephropathy, and glomerulonephritis (73).
Although physical findings are often absent, may be nonspecific,
or very discreet, many PIDs have characteristic features. A com-
mon feature in PID patients is failure to thrive (child) or wasting
(adult). Facial abnormalities, such as microcephaly or dysmor-
phism, are characteristic in some PIDs. Neurological abnormalities
can include ataxia, peripheral neuropathy, speech delay, mental
retardation, retinal lesions, photophobia, convulsions, or psy-
chomotor retardation, whereas gastrointestinal abnormalities ap-
pear as severe gingivostomatitis, recurrent aphthae, periodontitis,
delayed shedding of primary teeth, palatal weakness/cleft, gastric
outlet obstruction, or diarrhea (1, 2, 39–41).
Ligamentous laxity/hyperextensive joints, limited extension of
elbows, costocondral junction abnormality, rib abnormalities, me-
taphyseal chondrodysplasia/dysostosis, pectus carinatum, spondy-
loepiphyseal dysplasia, hip degeneration, or short limb dwarfism
are among the skeletal abnormalities found in PIDs (74). The skin
is frequently affected in immunodeficiencies. Erythroderma, eczema/
atopic dermatitis, pyoderma, or granuloma is common. The pres-
ence of petechiae or bruises suggests a bleeding problem, as in
phagocyte disorders (75–79).
The definitive diagnosis of PIDs depends on laboratory evi-
dence, including assessments of humoral and cellular immunity
and molecular analysis. The immunologic phenotype is based on
laboratory tests of immune function, such as serum Ig levels, spe-
cific Ab titers, peripheral blood lymphocyte subpopulations, mea-
sures of T cell function, assays of phagocytes, and complement
function or serum component level (1, 2, 37, 39–41).
Most of the parameters have binary values (yes, no), whereas,
for example, the laboratory parameters are quantitative. The pa-
rameters were chosen so that they represent different important
features of PIDs.
The new PID classification
The obtained 11 disease clusters are very robust due to them be-
ing the consensus of at least five methods. The p values show the
significance of the observations. More detailed subgrouping is
available by using the consensus of all the six methods. In Fig. 1A,
diseases coclustered by all the six methods are within the boxes,
whereas in the DCs at least five methods agree on the placement
of PIDs within the graph. In addition to the actual classification,
the PID parameters could offer guidelines for medical descriptions
of PIDs. The classification allows a novel and fresh look at the
relationships of PIDs, the genes behind them, and the encoded
proteins. The network is far more complex than the previous
mainly cell-type-based groupings might have led to imagine.
Based on the classification and the parameters, it might be possible
to develop novel diagnostic schemes for PIDs.
The correlation with other independent information not used for
the original classification implies that the classification reliably
reflects numerous properties of the diseases and the genes and
proteins mutated in them. Data for the disease parameters were not
complete, especially for the ultra-rare PIDs, and thus the homo-
geneity of the groups could even increase in the future when more
reliable statistical information for the symptoms and laboratory
characteristics will be available.
Diseases affecting genes involved in the same pathway do often
cocluster, and they share a similar etiology, for example, JAK3 and
IL2RG, and proteins in IFN-mediated immunity, including STAT1
and IFNGR2; MHC II diseases in DC III are all parts of the same
protein complex as well as the MHC I components in DC V; com-
plement components are in DC V and IX, and components of
membrane bound oxidase in DC XI; BLNK, BTK, and MyD88,
which have been suggested to be downstream of CD19 signaling,
are all in DC V.
The new PID classification resulting from our approach can have
several applications. Because it was generated independently from the
existing classifications using solely mathematical analysis of clinical
CAPS, cryopyrin-associated periodic syndromes; Crohn’s, Crohn’s disease; CN_ELA2, cyclic neutropenia; ELA2, severe congenital neutropenia; FCAS,
familial cold autoinflammatory syndrome; MWS, Muckle-Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease; WAS, Wiskott-
Aldrich syndrome; and XLN, X-linked neutropenia. OS denotes Omenn syndrome, in which multiple disease genes were identified. Independent properties
of the diseases and their respective proteins have a rather homogeneous distribution with the disease clusters for B, disease severity; C, therapeutic options;
D, functional properties of proteins; and E, vulnerability of the nodes in the PID protein interaction network. For supporting statistical parameters, see
supplemental Table S2. The color-coded properties are shown in each subgraph.
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and laboratory parameters, it can be used in evaluation and develop-
ment of other classifications. Disease groups defined by experts and
found also by our independent approach have a strong indication of
their existence. The new classification will be used in IDR (4) for
organizing diseases and information about them. Another possible
application is detailed demographics and mortality records.
The classification and the dataset also serve the development of
diagnostic expert systems, which requires objective criteria for diag-
nosis. Expert systems are useful, especially in case of rare diseases
like PIDs. The computer-based disease classification applied in this
study can also identify the key symptoms and laboratory parameters
that can help the experts to diagnose correctly these diseases.
The approach can be applied also to other groups of diseases.
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